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ABSTRACT 
 
 
 
Zinc has been recognized as one of the most versatile of all the minerals in the 
human body.  A large body of evidence has reported the critical role of zinc in human 
diet and that zinc deficiency is associated with numerous pathologies including 
growth retardation and delayed cognitive development.  However, zinc has also been 
studied because of its potential role in neurotoxicity. This perspective stands apart 
from traditional biology of zinc, because it concerns the disruption of zinc 
homeostasis in the body, as opposed to the zinc-related cellular dysfunction, which is 
caused by either zinc excess or deficiency. Altered zinc homeostasis has been 
reported to contribute to the progression of Alzheimer’s disease (AD) by inducing 
neuronal cell apoptosis and the formation of beta amyloid (Aβ). 
 
Docosahexaenoic acid (DHA), the most abundant long-chain polyunsaturated fatty 
acid in the brain, plays a significant role in regulating cellular zinc uptake. It has been 
shown that consumption of DHA is associated with a reduced incidence of 
neurodegenerative diseases and neuronal apoptosis, which are possibly mediated by 
reduction in zinc toxicity. Therefore, the main focus of this thesis concerns the 
molecular interaction between zinc and DHA that may provide a potential molecular 
mechanism to explain the beneficial effects of dietary DHA against zinc-induced 
neurotoxicity caused by excess zinc fluxes. 
XXI 
 
Chapter 2 aimed to characterize the effect of elevated [Zn2+]i  in mitochondrial 
function and whether DHA would protect against any zinc mediated alterations in 
bioenergetics. The results showed a decrease in cellular oxygen consumption rate in 
M17 human neuroblastoma cells, but not glycolytic rate in response to chronic zinc 
exposure, which was specific for neuronal cells. Zinc was also found to impair 
adenosine triphosphate (ATP) turnover, which was restored by DHA. These data have 
demonstrated that zinc disrupts bioenergetics at a point distal to the respiratory 
chain, which is restored by DHA.  
 
Coenzyme Q10 (CoQ10), an essential cofactor involved in the mitochondrial electron 
transport chain, is well characterized as a neuroprotective antioxidant and like DHA it 
has been suggested as a potential therapeutic agent in AD. In Chapter 3, the effect of 
CoQ10 and DHA against Aβ- and zinc-mediated changes in the mitochondrial function 
was investigated. The results showed that CoQ10 may be protective against Aβ-
induced alteration in basal respiration, ATP turnover, uncoupled respiration, maximal 
respiratory capacity, and mitochondrial membrane potential, whereas DHA had no 
significant effect on these mitochondrial parameters against Aβ toxicity. DHA, due to 
its direct molecular interaction with zinc, may specifically protect against zinc-
mediated mitochondrial alterations in M17 neuroblastoma cells.   
 
In Chapter 4, the aim was to investigate the interaction between zinc and DHA at the 
genomic and proteomic levels. In this study, histones were identified as the proteins 
XXII 
 
that were differentially expressed in response to zinc and DHA treatments. The 
proteomic analysis showed that expression levels of histones H3 and H4 were 
significantly decreased by zinc and increased following DHA treatment.  It has been 
reported that histone and DNA synthesis are very tightly linked. Therefore, the 
pathophysiological levels of zinc may possibly inhibit DNA synthesis, which result in 
the reduced expression of histones in M17 cells. DHA has shown to increase histone 
expression back to the basal levels, indicating the ability of DHA to protect the cells 
and abolish the effect of zinc toxicity. Increased DHA may play significant roles in 
DNA synthesis and stability, which is therefore associated with the increase in 
histone protein levels. 
 
Histones are also potentially important carriers of epigenetic information. In the next 
chapter, using M17 neuroblastoma cells, the effect of zinc and DHA on post-
translational modifications (PTMs) of histones, in particular histone H3 was 
elucidated (Chapter 5). In response to pathophysiological zinc concentration, there 
were significant increases in deacetylation, methylation and phosphorylation of 
histone H3 and significant decrease in acetylation of histone H3, all pointing towards 
possible gene silencing and apoptosis. Using Western blot technique, the level of 
anti-apoptotic Bcl-2 and pro-apoptotic caspase-3 were also evaluated. Indeed, zinc 
reduced the levels of the anti-apoptotic marker Bcl-2 while increasing the apoptotic 
marker caspase-3 levels.  Conversely, increase in DHA resulted in significant increase 
in acetylation of histone H3 and Bcl-2 levels and significant decreases in 
XXIII 
 
deacetylation, methylation, phosphorylation of H3 and caspase-3 levels, suggesting 
that DHA promotes gene expression and neuroprotection. The present findings have 
demonstrated that zinc and DHA have distinct epigenetic patterns, which suggest 
their opposing effect in the progression of neurodegenerative diseases.  
 
In summary, several intracellular targets for Zn2+-mediated neurotoxicity have been 
identified, which may provide the potential mechanism in which zinc toxicity leads to 
cellular apoptosis and neurodegenerative conditions. This thesis specifically 
emphasizes the direct interaction of DHA against zinc-induced mitochondrial 
dysfunction and involvement of bioenergetic regulation as a Zn2+ toxicity target, 
which may be the initiator of oxidative stress, caspase cascade, alteration in 
epigenetic patterns and therefore gene expression in human neuronal cells.   
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CHAPTER 1 
LITERATURE REVIEW ON MOLECULAR INTERACTION BETWEEN ZINC 
AND DOCOSAHEXAENOIC ACID (DHA) IN HUMAN NEURONAL CELLS 
 
PUBLICATION (Book chapter): 
Nadia Sadli, Nayyar Ahmed, M. Leigh Ackland, Andrew Sinclair, Colin J. Barrow and 
Cenk Suphioglu (2011). Effect of Zinc and DHA on Expression Levels and Post-
Translational Modifications of Histones H3 and H4 in Human Neuronal Cells, 
“Neurodegenerative Diseases - Processes, Prevention, Protection and Monitoring”, 
Raymond Chuen-Chung Chang (Ed.), ISBN: 978-953-307-485-6, InTech publisher. 
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1.1  NEURODEGENERATIVE DISEASES             
As life expectancies are increasing and populations are ageing, neurodegenerative 
diseases have become a global issue [1, 2]. Neurodegenerative diseases such as 
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly, which is 
characterized by molecular changes in nerve cells that result in nerve cell degeneration 
and ultimately nerve dysfunction and cell death [3]. In 1995, Australia had a population 
of 18 million and 13,000 people were estimated to have dementia. It is predicted that 
Australia will have 25 million people in 2041, and 460,000 of these will have dementia 
[4]. In other words, while our total population will increase by 40%, our population with 
dementia will increase by more than three-fold [4]. 
 
The expected human lifespan is now longer than ever due to improved hygiene, the 
discovery of medicines such as antibiotics, and economic welfare. The consequences for 
this aging population are the increased incidence of age-related diseases. Therefore, 
treatments to prevent age-related neurodegeneration will have economic benefits as 
well as major impact on the quality of life of the patients [5]. A great deal is already 
known about the pathology of neuronal diseases, but the molecular mechanisms 
underlying many of these diseases remain unknown. Thus, more research is needed to 
find the cause and to improve the treatment methods for these significant mental 
health problems. 
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1.1.1 Risk factors associated with neurodegeneration 
The most consistent risk factor for developing neurodegenerative disease is aging [6-8]. 
While it is possible to develop dementia early in life, the chances of developing it 
increases dramatically as people get older [9]. Although AD can strike people in their 
30s, 40s, or 50s, the vast majority of cases of AD are diagnosed in people older than 65 
[10-12].  A family history of dementia, gender (women are more likely to develop 
dementia than men), a head injury in the past [13], atherosclerosis, high cholesterol,  
hypertension, diabetes and high homocysteine levels, excessive alcohol and tobacco 
consumption, exposure to environmental substances and non-healthy diets are some of 
the factors likely to increase risk of dementia [14, 15].  
 
While there are some risk factors that cannot be controlled, such as genetics or age, 
many risk factors can be managed through lifestyle changes or appropriate dietary 
intakes. These dietary and lifestyle interventions cannot stop people from developing 
dementia but they may reduce the risk [16-18].  The adequate omega-3 fatty acid intake 
is one example of dietary factors associated with a substantially reduced risk of 
neurodegenerative diseases [18-20]. 
 
1.2 PHYSIOLOGICAL ZINC IN THE NERVOUS SYSTEM 
Zinc is the second most prevalent trace element in the body and is present in 
particularly high concentrations in the mammalian brain [21], including synaptic vesicles 
where it is tightly bound to intracellular proteins and zinc finger-containing transcription 
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factors [22]. The concentration of intracellular free zinc in the brain is thought to be very 
low under physiological conditions [22, 23]. However, it can rise to >300 nM in response 
to injurious stimuli [24].                                                                                          
 
Zinc plays an important role in growth and development, the immune response, 
neurological function and reproduction [25]. Zinc is also a constituent of many enzymes 
and is essential for the proper function of various enzymes including carbonic anhydrase 
[26], RNA polymerase, and superoxide dismutase [27].  
 
The role of zinc in cognitive function has been studied extensively in both children [28] 
and the elderly [29]. Zinc deficiency during fetal life is associated with developmental 
delays and low serum zinc levels in elderly is linked with poor global cognitive function 
[30], particularly verbal function, and also increases stress [31, 32]. Zinc deficiency most 
often occurs when zinc intake is inadequate or poorly absorbed [27, 30, 33], when there 
are increased losses of zinc from the body or when the body’s requirement for zinc 
increases [33]. Nonetheless, despite its importance, recent studies have revealed that 
excess zinc release in the pathological condition is toxic to the central nervous system. 
Moreover, disruption of zinc homeostasis has been implicated in several 
neurodegenerative diseases, such as AD [34, 35], where excess extracellular synaptic 
zinc was found to induce the formation of amyloid plaques, the characteristic feature of 
AD brains [36, 37]. These studies suggest the link between an altered neuronal zinc 
homeostasis and neurodegenerative disease progression.  
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1.2.1 Neuronal zinc distribution 
Evidence from the literature suggests that there are three separate pools of zinc in the 
central nervous system: vesicular zinc, protein-bound zinc and free ionic zinc. Vesicular 
zinc is that which is sequestered in the pre-synaptic vesicles of a special class of zinc-
containing neurons that are localized primarily in limbic, cerebrocortical and 
corticofugal system [38, 39]. 
 
The vesicles are accessible to zinc-specific permeable dyes and staining methods, and 
therefore the zinc residing within them can be histochemically stained [40]. Zinc 
accumulates in these vesicles because of the presence of a zinc- transporter-3 (ZnT-
3)[41]. Upon synaptic stimulation, vesicular zinc is released along with glutamate into 
the synaptic cleft where it may regulate post-synaptic neuronal excitability [42, 43]. 
Although the vesicular zinc is only 5-15% of total zinc in the brain, it constitutes virtually 
100% of the histochemically reactive zinc in the brain [44], which could be used as an 
indicator of neuronal cell injury.  
 
The second pool of zinc is that which is bound into the structure of many zinc-containing 
enzymes in the brain. It has been reported that zinc ions are incorporated into these 
proteins at the time of synthesis [40], so this pool of protein-bound zinc is relatively 
stable and is only involved in the specific function of the zinc-containing enzymes.  Since 
protein-bound zinc accounts for nearly 85-95% of zinc in the brain, the quantitative 
studies of zinc levels will be dominated by enzymatic zinc pool [40].  
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The third pool, is the intracellular free zinc ([Zn2+]i), which  is located in the cytosol. Due 
to small amount of free zinc ions in the cells, it is difficult to study the Zn2+ dynamics in 
the cell. However, it is estimated that under normal conditions, the [Zn2+]i is 
approximately in the femtomolar to picomolar concentrations [23]. In fact, O’Halloran 
(2001) reported that there is no free zinc in the cell [23]. The rise and decline of [Zn2+]i 
depends on the mobilization of zinc between storage sites, metal chaperons and zinc-
bound proteins. While the amount and function of this free zinc ions are not completely 
understood, it is clear that the subtle increase in the level of [Zn2+]i are lethal to neurons 
[23, 45].  
 
1.2.2 Maintaining intracellular zinc homeostasis 
Maintaining a constant state of intracellular zinc homeostasis is essential for normal cell 
function. It has been reported that intracellular zinc ion concentration [Zn2+]i is 
maintained within the normal range (less than 10 – 12 M) by metal sensor proteins, zinc 
transporters, and zinc-binding proteins [23]. This extremely low free cytosolic zinc 
concentration is a reflection of the abundance of metal-binding components in the 
intracellular environment. These zinc regulatory systems act as switches that turn on or 
off depending on the condition of zinc excess or deficiency [23]. 
 
Metallothioneins (MTs) are a group of low-molecular-weight (6-7 kDa) intracellular 
proteins that bind to Zn2+ [46].  These metalloproteins are involved in the storage, 
transport, and biological properties of not only zinc, but also copper, cadmium and 
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mercury. A study has reported that MTs may also protect against inflammation through 
their antioxidant potential, and by suppressing inflammatory cytokines, such as 
interleukin-1 beta [47].  Other studies have also demonstrated that MT knockout cells 
and animal models exhibit increased susceptibility to oxidative damage [48, 49], 
whereas MT overexpression confers resistance to heavy metal toxicity [50].  
 
In addition to intracellular binding proteins metallothionein, zinc homeostasis in the 
brain is regulated and tightly controlled by zinc transporters, which are divided into two 
gene families: the ZnT proteins [solute-linked carrier 30 (SLC30)] and the Zip family 
[solute-linked carrier 39 (SLC39)][51, 52], to allow Zn2+ influx with deficiency and to 
remove cytosolic Zn2+ with toxic accumulations. ZnT and Zip proteins appear to have 
opposite roles in cellular zinc homeostasis. The function of ZnT transporters is to reduce 
intracellular cytoplasmic zinc by promoting zinc efflux from cells or into intracellular 
vesicles, while Zip transporters increase intracellular cytoplasmic zinc by promoting 
extracellular and perhaps, vesicular zinc transport into cytoplasm [53]. Table 1.1 lists the 
function of each zinc transporter that has been identified so far. 
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Table 1.1: Family of ZnT zinc transporters. 
ZINC 
TRANSPORTER 
LOCALIZATION TISSUE 
SPECIFICITY 
FUNCTION REFERENCE 
ZnT-1 Plasma 
membrane 
All cells Extrude 
cellular Zn2+ 
Liuzzi et al. [54] 
ZnT-2 Cytoplasmic 
vesicles 
All cells Store Zn2+ Liuzzi et al. [54, 
55] 
ZnT-3 Synaptic 
vesicles 
Brain and testis Store Zn2+ Cole et al. [56]; 
Smidt et al. [57] 
ZnT-4 Luminal cell 
vesicle 
Mammary 
gland 
Induce 
lactation 
Michalczyk et al. 
[55, 58] 
ZnT-5 Vesicles Pancreatic ß 
cells, ovary, 
testis 
Sequestration 
of Zn2+ 
Ventine et al. 
[59]; kambe et al. 
[60] 
ZnT-6 Golgi body Brain, lung, 
small 
intestine, liver 
Sequestration 
of Zn2+ 
Huang et al.[61] 
ZnT-7 Cytoplasmic 
vesicles 
Brain, lung, 
small Intestine, 
liver 
Sequestration 
of Zn2+ 
Kirschke et 
al.[62] 
ZnT-8 Vesicles Pancreas, liver Not yet known Wijesekara et 
9 
 
 
1.3 ZINC AND ALZHEIMER’S DISEASE (AD)                                                                 
The pathogenesis of AD is associated with two main phenomena: hyperphosphorylation 
of the tau protein resulting in its accumulation in the neurofibrillary tangles and the 
formation of β-amyloid (Aβ) that is deposited early and selectively in senile plaques [65, 
66]. 
 
Aβ is a 39-43 amino acid residue peptide derived from a large precursor protein amyloid 
precursor protein (APP) via endoproteolytic cleavage [67]. The aggregation and the 
conformational change of Aβ is strongly correlated with its neurotoxicity. Therefore, 
factors that promote the aggregation of Aβ may be involved in the pathologenesis of 
AD. One study has shown that APP expression is tightly regulated by zinc-containing 
transcription factors, which itself contains a zinc binding site [68]. Zinc has been 
reported to enhance the Aβ aggregation, mediated by its interaction with APP [69]. 
Apart from its interaction with zinc, APP has also been suspected to bind to copper and 
play a key role in regulating copper homeostasis [70]. Considering the low concentration 
of [Zn2+]i, a subtle increase is enough to initiate neurotoxicity and AD. It is possible that 
zinc may also influence the homeostasis of other trace metals such as copper and 
al.[63] 
ZnT-9 Cytoplasmic 
and nuclear 
vesicles 
Mammary 
gland 
Induce 
lactation 
Kelleher et al. 
[64] 
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aluminium, which have also been found to accelerate the aggregation of Aβ through 
APP interaction [71]. 
 
1.4 ZINC TOXICITY AND NEURONAL CELL DEATH 
Based on the evidence described above, increase in [Zn2+]i is toxic to the cells and can 
contribute to neurodegenerative diseases. Animal studies have shown that the 
detrimental effect of zinc accumulation could be overcome by treatment with a zinc 
chelator [72, 73], suggesting a reversible effect of zinc toxicity. Even though an 
unambiguous mechanism of Zn2+-mediated neurotoxicity has not been delineated, 
several possible pathways have been identified. It is likely that more than one 
mechanism is involved in zinc-induced neurotoxicity, which converges or acts in parallel 
to cause cell death.  
 
Apoptosis is an elimination process that plays an important role in cellular development. 
The activation of cell death program is regulated by many different signals that originate 
from the intra- and extracellular milieu. Apoptosis is characterized by DNA 
condensation, nuclear fragmentation, increase in plasma membrane permeability and 
cell shrinkage. Eventually, the apoptotic cell breaks into small membrane-surrounded 
fragments, which are cleared by surrounding cells [74]. All these events are tightly 
controlled and well organized. Dysregulation of apoptosis may lead to deviations from 
normal development and may cause or contribute to a variety of diseases, including 
cancer, neurodegenerative diseases and ischemic stroke (89, 90).  
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1.4.1 Mechanism of zinc-mediated toxicity leading to cellular apoptosis 
It is well documented that oxidant exposure can trigger the release of Zn2+ from 
intracellular stores [75], which may contribute to the initiation of cellular apoptosis and 
free radical accumulation [76]. The zinc-induced reactive oxygen species (ROS) 
production and cell apoptosis have also been found to overactivate protein kinase C 
(PKC), which is linked with calcium influx [77] and cell death [78]. This neuronal injury 
can be inhibited following application of PKC inhibitors or antioxidants [79], suggesting 
PKC-generated oxidative stress as one important mechanism in Zn2+-induced neuronal 
cell death. 
 
The mechanism of zinc-mediated apoptosis is considered relevant as many zinc-
dependent transcription factors required for normal cell function are impaired during 
apoptosis [23]. Evidence also showed that zinc-induced apoptosis is mediated by 
caspase-dependent mechanisms. It has been reported that zinc treatment increases 
caspase-3 protein (pro-apoptotic marker) and reduces Bcl-2 (anti-apoptotic marker) 
expression levels in M17 neuroblastoma cells [80], indicating a direct involvement of 
zinc-mediated caspase cascade in cellular apoptosis.  
 
Mounting body of evidence suggests that the dyshomeostasis of calcium ions may also 
be involved in the mechanism of zinc neurotoxicity. Upon increase in Zn2+ levels, zinc is 
translocated through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor-dependent Ca2+ channel, where they induce the elevation of intracellular Ca2+ 
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of neurons [81]. The elevated level of intracellular Ca2+ trigger various apoptotic 
pathways such as activation of calpain, caspases or other enzymatic pathways related to 
apoptosis [82, 83].  
 
Zinc has also been reported to affect mitochondrial function by inhibiting 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) (enzyme that involves in the 
glycolysis), and that pyruvate, the end product of glycolysis which acts as an energy 
substrate, attenuates zinc-induced death of neurons [84]. This suggests that inhibition 
of glycolysis and bioenergetic failure may be involved in the mechanism of zinc-
mediated toxicity. My works have also demonstrated that pathophysiological levels of 
Zn2+ causes loss of mitochondrial membrane potential (ΔΨm), enhances reactive oxygen 
species (ROS) production (Sadli et al. 2012 – manuscript submitted) and inhibits 
mitochondrial respiration [85], which may be due to inhibition of the electron transport 
chain. It has been reported that free zinc ions at about 100 nM are sufficient to 
depolarize mitochondria membrane potential and induce ROS production in neuronal 
cells [86]. This data shows the importance of maintaining zinc homeostasis, as the slight 
change in intracellular zinc ion concentration can lead to bioenergetic dysfunction. 
Based on the evidence described above, it has been suggested that mitochondria play 
an important role in regulating cell function and that there is no way to bypass 
mitochondria in the process of cell apoptosis and neurodegenerative conditions.  
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1.5  MITOCHONDRIA-MEDIATED APOPTOSIS  
Mitochondria are the energy powerhouse of cells, which generate life energy in the 
form of ATP, the main energy currency of the body [87, 88]. Mitochondria consist of: 1). 
An outer membrane that encloses the entire structure, 2). An inner membrane that 
encloses a fluid-filled matrix, 3). The intermembrane space, 4). The inner membrane, 
which is elaborately folded with shelf-like cristae projecting into the matrix and 5).  
Mitochondrial DNA (mtDNA) [89]. The inner membrane contains 5 complexes of integral 
membrane proteins: 1). Nicotinamide adenine dinucleotide (NADH)  dehydrogenase 
(Complex I), 2). Succinate dehydrogenase (Complex II), 3). Cytochrome c reductase 
(Complex III; also known as the cytochrome b-c1 complex), 4).  Cytochrome c oxidase 
(Complex IV), all make up the protein complex of the respiratory chain and 5). The ATP 
synthase (Complex V) [90].  These protein complexes manage the process of oxidative 
phosphorylation, which begins as complex I engages NADH and complex II engages 
Flavin Adenine Dinucleotide (FADH2). Energy is released when electrons are transported 
from higher energy NADH/FADH2 to lower energy O2 [91].  Each enzyme strips away the 
pair of electrons from its substrate and passes them to coenzyme Q10 (CoQ10). CoQ10 
is a small molecule that shuttle electrons from complexes I and II to complex III, while 
also providing potent antioxidant protection for the inner membrane oxidative 
phosphorylation complex [92]. CoQ10 is an important nutrient and CoQ10 deficiencies 
are associated with subnormal or pathological mitochondrial performance [93]. CoQ10 
has also been shown to reduce the symptoms of neurodegeneration [94, 95].  
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During an apoptotic stimulus, the permeability of the mitochondrial membrane is 
disrupted, which is called the mitochondrial permeability transition (MPT). The MPT is 
characterized by rapid permeability of the mitochondrial membrane and release of 
apoptosis-mediator proteins from the intermembrane space into the cytosol. This 
membrane permeabilization implies the formation of pores or channels that cause the 
dissipation of the membrane potential across inner mitochondrial membrane, which is 
associated with disruption of the electron transport chain [90]. As a result of impaired 
electron transport chain, the ATP production is depleted and electrons escape from the 
respiratory chain to form ROS [96]. This ROS generation is intrinsic to the oxidative 
phosphorylation process and has potential to destroy the cells, usually beginning with 
the mitochondria themselves. As the mitochondria progressively lose their functional 
integrity, ever greater proportion of oxygen molecules are converted to ROS. Since free 
radical reaction self-propagate, additional ROS produced subsequently results in the 
destruction of fatty acids and cell-membrane phospholipids, as well as DNA 
fragmentation [97, 98]. Antioxidant enzymes, as well as the DNA and protein-repair 
enzymes themselves, can become damaged and no longer provide cellular protection. 
Mutations due to ROS attack can also accumulate along with malfunctioning molecules 
and other debris. Eventually, the cell is either crippled, killed outright (necrosis), 
commits suicide (apoptosis), or loses growth control and becomes cancerous [88]. 
 
Another consequence of the MPT can be swelling of the matrix and rupture of the outer 
membrane, allowing release of apoptotic mediator proteins from the mitochondria. 
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Western immunoblot detection of such proteins, such as cytochrome c (cyt c), adenylate 
kinase (ADK) and apoptosis-inducing factor (AIF) in cysotol and nuclei (the 
extramitochondrial compartment), indicates a sign of outer mitochondrial membrane 
permeabilization [99]. 
 
Proteomic analysis has also revealed that apart from cyt c and AIF, there are other 
numerous key proteins that are released from the mitochondrial membrane, which 
includes procaspase, Smac/DIABLO (mitochondria-derived activator of caspase/direct 
inhibitor of apoptosis protein (IAP)-binding protein antagonist) [100], Omi/HtrA2 (high-
temperature requirement protein A2) and Endonuclease G (enzyme contribute to 
apoptotic nuclear DNA damage in a caspase-independent way)[101, 102].  
 
Factors released from the mitochondria are crucial for the activation of pro-apoptotic 
signaling. During apoptosis, cyt c (an electron shuttle molecule) is released from 
mitochondria complexes with apoptosis protease-activator factor 1 (Apaf-1), 
cytochrome c/2'-deoxyadenosine 5'-triphosphate (dATP) and cytosolic pro-caspase-9 to 
form a caspase-activating complex called the apoptosome. Cyt c and dATP induce 
refolding of Apaf-1, which allows interaction with pro-caspase-9. In this way, pro-
caspase-9 is activated, which subsequently cleaves and activates caspase-3 [103]. 
Depending on cell type and stimulus, caspase-3 can be involved in the activation of 
procaspase-8, procaspase- 6, pro-caspase-9 and BH3 (The Bcl-2 homology domain 3)-
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domain-only subgroup of Bcl-2 family member (BID) that results in a feedback 
amplification of the apoptotic signal [104].   
 
1.6  LINK BETWEEN CELLULAR APOPTOTIS AND NEURODEGENERATIVE DISEASES 
A characteristic of many neurodegenerative diseases, such as AD, Parkinson’s disease 
and stroke, is neuronal cell death [105, 106]. Central nervous system (CNS) tissue has 
very limited regenerative capacity and therefore, it is important to limit the damage 
caused by neuronal cell death [107, 108]. In recent years, the investigation regarding the 
contribution of caspases and neuronal apoptosis to neurodegenerative diseases has 
gained increasing attention. This evidence has been generated by using a variety of 
complementary approaches, including evaluating human tissue and using transgenic 
mouse and in vitro models [108]. 
 
Studies have shown the imbalance levels of pro-apoptotic (Bax, Bak and Bad) and anti-
apoptotic Bcl-2 proteins [109, 110], as well as caspase-3 and -6 in the brain of AD 
patients [111]. In addition, immunohistochemical and biochemical studies reported the 
presence of active caspases and caspase-cleaved substrates around senile plagues and 
neurofibrillary tangles in neuron [112]. A marked co-localization of 
hyperphosphorylated tau, caspase-3 and caspase-6 in Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL)-positive neurons in the brainstem of AD 
patients [113] were also observed, indicating the potential involvement of apoptotic 
death in the etiology of AD.  
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Caspase-mediated apoptotic pathways have specifically been linked to the progression 
of AD, especially toward the formation of amyloid precursor protein (APP) and Aβ 
peptide production. Caspase-3-mediated APP stabilizes BACE1 (the β-secretase enzyme 
that is responsible for the cleavage of APP and the associated creation of Aβ), which 
lead to an increase in Aβ formation [114]. Studies also indicate that caspases have been 
implicated in the mechanism of tau-mediated neurodegeneration of AD [115]. 
According to this hypothesis, Aβ peptide was reported to promote neuronal 
pathological tau filament assembly by triggering caspase activation leading to tau 
cleavage, which in turn generate more tau pathological filaments [114] that further 
contribute to increase of cellular dysfunction in AD [116]. 
 
The balance between pro-apoptotic and anti-apoptotic pathways determine the 
outcome of cell death upon a stimulus. As long as protective proteins are present in high 
amounts, the balance will be in favor of cell survival. Therefore, understanding of cell 
survival mechanisms is essential to study the mechanism of zinc-mediated cellular 
dysfunction and the potential therapeutic treatment to inhibit zinc toxicity and cellular 
apoptosis.  
 
Recently, the role of polyunsaturared fatty acids (PUFAs) docosahexaenoic acid (DHA) in 
the brain has been examined, as they are associated with the reduction of 
neurodegenerative diseases such as AD, and found to be neuroprotective against cell 
apoptosis through maintaining zinc homeostasis.   
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1.7 POLYUNSATURATED FATTY ACIDS (OMEGA-3 PUFAs) 
1.7.1 Metabolism of PUFAs  
Fatty acids (FAs) are carboxylic acids with a long side chain of hydrocarbons. FAs with 
only single bonds between adjacent carbon atoms are referred to as “saturated”, 
whereas those with at least one C=C double bond are called “unsaturated” [117] (see 
Table 1.2 below for a list of common fatty acids).  
 
Table 1.2: List of common fatty acids arranged in different classes.  
COMMON NAME SCIENTIFIC NAME MOLECULAR 
NAME 
ABBREVIATION 
Saturated fatty acids 
Lauric acid Dodecanoic acid 12:0  
Myristic acid Tetradecanoic acid 14:0  
Palmitic acid Hexadecanoic acid 16:0  
Stearic acid Octadecanoic acid 18:0  
Arachidic acid Eicosanoic acid 20:0  
Behenic acid Docosanoic acid 22:0  
Lignoceric acid Tetracosanoic acid 24:0  
Monounsaturated fatty acids 
Vaccenic acid 11-octadecenoic acid 18:1n-7  
Oleic acid 9-octadenoic acid 18:1n-9  
Omega-3 polyunsaturated fatty acids 
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The PUFAs, which contains more than one double bond, can be classified according to 
the position of the last double bond closest to the terminal methyl carbon, such as 
omega-3 (n-3) and omega-6 (n-6) series PUFA. For example, docosahexaenoic (DHA) is 
an omega-3 (n-3) FA with 22 carbon atoms and six double bonds, usually in an all cis 
configuration (Fig. 1.1).  
 
α-linolenic acid 9,12,15-octadecatrienoic 
acid 
18:1n-3 ALA 
Eicosapentanoic 
acid 
5,8,11,14,17-
eicosapentaenoic acid 
20:5n-3 EPA 
Docosapentaneoic 
acid 
7,10,13,16,19-
docosapentaenoic acid 
22:5n-3 DPA 
Docosahexaenoic 
acid 
4,7,10,13,16,19 – 
docosahexaenoic acid 
22:6n-3 DHA 
Omega-6 polyunsaturated fatty acids 
Linoleic acid 9,12-0ctadecadienoic acid 18:2n-6 LA 
γ-linolenic acid 6,9,12-octadecatrienoic acid 18:3n-6 GLA 
Arachidonic acid 5,8,11,14-eicosatetraenoic 
acid 
20:4-6 AA 
n/a 4,7,10,13,16-
docosapentaenoic acid 
22:5n-6  
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Figure 1.1: Linear schematic diagram of Docosahexaenoic acid (DHA, 22:6n-3).  
 
As the degree of unsaturation in FAs increase, the melting point decreases, which confer 
the attribute of fluidity of n-3 PUFAs in cell membranes that influence many aspects of 
cell function [118]. EPA and DHA are synthesized from the n-3 precursor of α-linolenic 
acid (ALA, 18:3n-3) [119, 120], whereas the long chain n-6 PUFAs, such as arachidonic 
acid (AA, 20:4n-6), are synthesized from the predominantly plant-derived precursor 
linoic acid (LA, 18:2n-6)  [121]. ALA are predominantly available from plant oils such as 
canola, soybean and flaxseed [122]. Major source of LA are corn, sunflower oil and 
safflower oil [123]. The ability of enzymes to produce the omega-6 and omega-3 family 
of products of LA and ALA declines with age. Study showed that desaturase enzyme 
function in old rats was only 44% of the desaturase function in young rats [124]. Since 
DHA synthesis declines with age, as we get older our need to acquire DHA directly from 
diet or supplements increases. Figure 1.2 shows the desaturation and elongation 
cascade of omega-3 and omega-6 series PUFAs. 
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Figure 1.2: Digrammatic representation of the omega-6 and omega-3 series metabolic 
pathway. The essential precursors, α-linolenic and linoleic acid undergo a number of 
desaturations (addition of double bonds) and elongation reaction (addition of carbon 
atoms) and end up as long chain omega-6 and omega -3 PUFA. The enzymes for each 
step are written in italics.  
 
1.7.2 Role of docosahexaenoic acid (DHA) in cellular function  
Docosahexaenoic acid (DHA) is the predominant omega-3 fatty acid in the brain of 
mammals, which comprises up to 15% of the concentration of fatty acids in the nervous 
system [125]. Epidemiological studies suggest that dietary DHA, which is commonly 
found in fish [126], may modify the risk for certain neurodegenerative disorders [127]. 
Indeed, decreased blood levels of omega-3 FAs have been associated with several 
neurodegenerative conditions, including AD, schizophrenia and depression [128, 129]. 
Communities with regular consumption of fish have shown to possess reduced 
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prevalence of neurodegenerative disease and cognitive decline in general [128, 130, 
131].  DHA can be linked with many aspects of neural function, including 
neurotransmission, membrane fluidity [132], ion channel [133], enzyme regulation [134] 
and gene expression [135]. DHA is found in breast milk, and may be required for early 
visual [136] and brain development in children [137, 138]. Furthermore, studies in 
animal models have provided support for the protective role of omega-3 FAs. For 
example, mice fed on diets high in omega-3 FAs were shown to improve in neurological 
function, such as better regulation of nerve cell membrane excitability [139], increased 
levels of neurotransmitters and higher density of neurotransmitter membrane receptors 
[140]. Hossain et al (1998) found that administration of DHA leads to the improvement 
in memory function and reduction in free radical levels while maintaining high level of 
antioxidant enzyme, indicating a role of DHA in antioxidant defense [141]. Study by 
Calon et al (2004) has reported that dietary DHA also protects the cells against apoptosis 
by decreasing caspase activity [142], while others have supported this finding by 
showing that the enrichment of dietary DHA prevents apoptosis under damaging 
conditions [143]. DHA also increases phosphotidylserine levels (PS) in neuronal 
membrane, which result in Akt translocation [144] and contributes to survival signaling 
by suppression of caspase-3 [145]. 
 
1.8 MOLECULAR LINK BETWEEN ZINC AND DHA IN NEURONAL CELLS  
The alteration in both DHA and zinc homeostasis are key features of neurodegenerative 
disorders [146, 147]. A study by Jayasooriya et al (2005) has demonstrated the link 
23 
 
between an altered zinc homeostasis in the brain of rats fed on an omega 3-deficient 
diet [148]; this diet led to a significant decrease in brain DHA levels. Though these data 
have shown a relationship between DHA and zinc homeostasis, the basis of a molecular 
mechanism has not been elucidated.  
 
This fundamental finding has been used to investigate the molecular mechanisms 
underlying this zinc and DHA interaction. Using human neuroblastoma cell line M17, the 
recent data have shown that DHA reduces cellular zinc uptake, possibly mediated by the 
zinc transporter ZnT3 followed by a significant reduction in pro-apoptotic marker, 
caspase-3 [45]. This indicates the effect of DHA deficiency in the progression of 
neurodegenerative disease, which is partly mediated by altered zinc fluxes. In M17 cells, 
the expression of these two zinc transporter families, including Zip1, Zip2, Zip3, Zip4, 
Znt1, ZnT2, ZnT3, ZnT4, ZnT5, ZnT6 and ZnT7 were detected [45]. ZnT3 has been the 
focus of the previous studies, as it is associated with brain zinc accumulation, as well as 
AD, the condition where the expression was found to be up-regulated [149]. 
 
As previously discussed, the alteration of zinc metabolism may play a significant role in 
cellular apoptosis, which is a key feature in the pathology of neurodegenerative 
disorders such as AD [150]. Using Western blot analysis of human neuroblastoma M17 
cell line, a link between DHA treatment and inhibition of apoptosis was observed, where 
more than 66% reduction in active caspase-3 protein level was detected in cells treated 
with 20 µg/ml DHA, compared with the untreated control [45]. The suppression of 
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activated caspase-3 may be mediated by phosphatidylinositol 3-kinase-dependent 
pathway resulting in the phosphorylation of Akt and DHA may act through this pathway. 
Akbar et al (2005) reported the beneficial effect of DHA in neurosurvival through an 
increase in phosphatidylserine concentration, which resulted in translocation and 
phosphorylation of Akt suppressing the activation of caspase-3 [144]. Zinc, on the other 
hand, directly activates Akt by phosphorylation at Ser-473/Thr-308 in H1907 embryonic 
hippocampal cells, leading to activation of GSK-3beta and cell death [151]. This suggests 
that DHA inhibits apoptosis through decreasing intracellular zinc ion concentration, 
which leads to an increase in Akt activity and neuronal survival. 
 
In summary, dietary DHA deficiency is associated with neurodegenerative conditions, 
which have been shown to be a factor in zinc toxicity. DHA also inhibits cellular apoptosis 
in M17 cells through decreasing cellular zinc uptake and reduction of ZnT3 mRNA and 
protein levels. Therefore, zinc homeostasis may play an important role in neuronal cell 
survival and altered zinc homeostasis may contribute to the development of 
neurodegenerative diseases. 
 
This thesis focus only on the effects of DHA, which is based on the preliminary data that 
zinc fluxes is regulated by DHA in human neuronal cells.  Other fatty acids such as EPA and 
DPA will be investigated in the future. 
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1.9 ZINC AND DHA INTERACTION MEDIATED BY HISTONES 
The links between zinc and DHA interaction in gene regulation using proteomic and 
genomic analysis have also been investigated. Recently, histones were found to be 
regulated by both zinc and DHA [152]. Following this novel finding, it is important to 
gain an understanding on how these two nutrients involved in neuroprotection, which 
are mediated by histones. 
 
1.9.1  Histones are involved in the assembly of chromatin  
The activity of transcription is not only due to the regulation of DNA [153], but also to 
the  structure of chromatin which plays a role in transcriptional regulation. Histones, the 
nucleosomal proteins, can be modified in several ways, which further affects the 
regulation of gene expression [154]. 
  
Histones are a group of conserved, highly basic proteins that are rich in lysine (K) and 
arginine (R) [155-158] (Table 1.3).  Histones are involved in the assembly of chromatin 
through electrostatic interaction between the highly negatively charged polymeric DNA 
and the positively charged histones, which play a determining role in stabilizing the 
nucleosomes at physiological conditions [159]. About 85% of the DNA in chromatin is 
represented by uniform units, the nucleosomes, which are the complexes of DNA 
double helix with five histone proteins (H2A, H2B, H3, H4, and H1)[160]. The central part 
of the nucleosome is called the nucleosome core particle and consists of 147 bp DNA 
wrapped around the histone octamer which is formed from one (H3/H4)2 tetramer and 
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two H2A/H2B dimers [160, 161] (Fig. 1.3). The four core histones have similar isoelectric 
points (PI) and share a common structural motif called the histone fold, which facilitates 
the interactions between the individual core histones [162]. Flanking the core domains 
are the relatively N-terminal unstructured tail domains.  The histone tails extend out 
from the face of the nucleosome and through the gyres of DNA superhelix into the area 
surrounding the nucleosome [160]. In contrast to the structural core histone proteins, 
histone H1 is associated into linker DNA, which connects the nucleosomes together, 
resulting in the formation of “beads-on-a-string” chromatin structure [163].  
 
Table 1.3: Characteristics of histones. Molecular weight (MW) is given in Daltons (Da) 
and isoelectric points (PI) are shown. 
 
HISTONE 
TYPE 
CLASS (AMINO ACID 
DISTRIBUTION)  
M.W (Da) SEQUENCE 
LENGTH  
ISOELECTRIC 
POINT  (PI) 
H1 Very lysine rich 21,500 215  
H2A Lysine rich 14,004 129 10.9 
H2B Lysine rich 13,774 125 10.3 
H3 Arginine rich 15,324 135 11.1 
H4 Arginine rich 11,282 102 11.4 
 
 
1.9.2  Histone post-translational modifications (PTMs) and gene activities 
In addition to nucleosome assembly, studies have found that histones are potentially 
important carriers of epigenetic information and therefore play significant role in 
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regulating gene activities, such as DNA damage repair, replication and transcription 
through post-translational modifications (PTMs)[164]. The N-terminal tail domain of the 
core histones serve as a substrate for histone modifying enzymes to introduce PTMs 
such as acetylation, methylation, phosphorylation, ubiquitylation and sumoylation [165, 
166]. Some modifications such as acetylation and phosphorylation can modify the 
charge of the histone tails and therefore potentially influence the chromatin remodeling 
through electrostatic mechanisms. However, the primary mechanism by which the 
histone tail modification act is mainly through regulation of the binding of non-histone 
protein to chromatin [167-169]. 
 
 
Figure 1.3:  Crystal structure of nucleosome (Luger et al., 1997). Ribbon traces for the 
146 bp DNA phosphodiester backbones (brown and turquoise) and eight histone protein 
main chains (blue: H3; green: H4; yellow: H2A; red: H2B). Left: nucleosome particle 
viewed down the DNA superhelix axis. Right: perpendicular position to DNA [170].  
 
PTMs of histones, alone or in combination, function to direct specific and distinct DNA-
templated programs, and therefore give rise to “histone code“ hypothesis [171]. This 
hypothesis predicts that histone tail modification act as a binding site for recruitment of 
protein complexes to the nucleosome, which may further modify and regulate 
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chromatin accessibility [171]. The reversible acetylation and deacetylation of histone 
emerged to play an important role in chromatin modification [172] and gene activity 
regulation, which affect a variety of biological processes in response to internal and 
external signals, such as cell differentiation, growth and development [173]. The sites of 
acetylation include four highly conserved lysines in histone H4 (K5, K8, K12 and K16), 
five in histone H3 (K9, K14, K18, K23 and K27), as well as less conserved sites in histone 
H2A and H2B [174].  The acetylation acts by neutralizing the positive charge of the 
histone tails and weakens the electrostatic interactions between the histone and the 
DNA backbone [175, 176]. This allows the transcription activators and the basal 
transcription machinery to have better access to their specific binding sites in the gene 
promoter and enhancer sites [176], which therefore increasing  gene transcription [172].   
Recent studies have shown that when DNA is assembled onto the nucleosome with 
unacetylated histones, the general transcription factors cannot bind to the TATA box 
and the initiation region. By being unacetylated, the N-terminal lysines are positively 
charged and interact strongly with the DNA phosphates increasing the affinity of the 
DNA for the nucleosome. Therefore, a hyperacetylation of histone N-terminal tails is 
necessary in order for transcription factors to bind and initiate transcription [160, 165, 
170]. 
 
The opposite effect of histone acetylation is deacetylation, also known as 
hypoacetylation status, which is associated with chromosome condensation, 
transcriptional repression and gene silencing [177].  This deacetylation state of histone 
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stabilizes the repressive state of the nucleosome through strengthening the 
electrostatic interaction between negatively charged DNA molecules and the positively 
charged lysine residues [178].  Basically, histone acetylation acts as a central switch that 
allows interconversion between permissive and repressive chromatin structures and 
domains, which govern gene transcription regulation and processes involving chromatin 
substrates, including replication, DNA recombination and repair [179].  
 
Another PTM is the methylation. Specific methylation of lysine residues is known to 
occur on histone H3 at K4, K9, K27, K36 and K79 and on histone H4 at K20. Arginine 
methylation takes place on histone H3 at R2, R17 and R26, and on histone H4 at R3 
[180]. Like histone acetylation, methylation can also modulate histone interaction with 
DNA, which then results in the alteration of nucleosomal structure and function. 
Therefore, it is involved in various biological activities, ranging from transcription 
regulation [181] to epigenetic silencing [182]. Lysine residues may be modified to either 
mono-, di- or trimethylated states, adding more complexity to this code [181]. 
 
It has been extensively reported that histone H3 at position K9 is a site for both 
acetylation and methylation, which lead to the formation of either euchromatin or 
heterochromatin, depending on the type of modification [180]. In general, methylation 
of histone H3(K4), -(K36) and -(K79) are correlated with euchromatin and transcriptional 
activation, while methylation of histone H3 (K9) and -(K27) and histone H4 (K20) are 
associated with heterochromatin and transcriptional repression [183].  Whether these 
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PTMs of histones have a role in setting the boundaries between heterochromatin and 
euchromatin, they also play important role in other biological activities such as DNA 
repair system [184], maintenance of DNA methylation [185] and apoptosis [186]. For 
instance, study by Huyen et al (2004) reported the involvement of histone H3 (K79) 
methylation in DNA repair by recruiting the DNA repair-associated protein, 53BP1, 
which specifically binds to methylated H3 (K79) [184]. Histone H3 (K9), apart from its 
association with heterochromatin region, is also required for the maintenance of DNA 
methylation [185]. The combination of enhanced histone and DNA methylation have 
been found to silence one of the copies of the X-chromosome in female mammals [187]. 
However, different histone modifications can possibly interact by antagonizing or 
cooperating with one another, which give various different outcomes in regulating cell 
activities [188]. Study by Nishioka et al (2002) reported the antagonizing function of H3 
(K4) methylation (activation) and the H3 (K9) methylation (repression) in transcriptional 
control [189]. Furthermore, in vitro and in vivo studies have shown that methylation of 
H4 (K20) inhibits the acetylation of H3 (K16), which is a  marker for hyperactive male X-
chromosome in Drosophilla [190] and transcriptionally active chromatin in human cells 
[191]. Taken together, histone methylation may play significant role in gene regulation 
and therefore contributes to the epigenetic control of biological activities.  
 
In addition to acetylation and methylation, phosphorylation is also involved in gene 
activities.  Histone phosphorylation takes place at threonine 3 and 11 and at serine 10 
and 28 residues and has been shown to be involved in cell cycle progress during mitosis, 
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meiosis [192],  as well as transcriptional activation of immediate early-response genes, 
such as c-fos, c-myc and c-jun during interphase [193]. On the other hand, Enomoto et 
al (2001) suggested that histone phosphorylation, especially H2A, H3 and H1, is an early 
step of triggering DNA fragmentation in apoptosis [194].  
 
1.9.3   Enzymes involve in histone post-translational modifications (PTMs) 
Histone acetylation is a dynamic process that is regulated by two classes of enzymes, the 
histone acetyltransferases (HATs) and histone deacetylases (HDACs) [195]. HATs family is 
classified into two categories based on their subcellular distribution, type A and type B 
HATs [179].   
 
The type A HATs are responsible in acetylation of histones within chromatin and 
therefore directly involved in regulating chromatin assembly and gene transcription 
[196]. Type A HATs consist of transcriptional activator Gcn5-related acetyltransferases 
(GNATs), PCAF (p300/CBP-associated factor), the transcriptional coactivator p300/CBP, 
MYST (for MOZ, Ybf2/Sas3, Sas2 and Tip60)-related HATs and TAFIID subunit TAF250, 
which have counterparts in eukaryotes including plants [196, 197]. Additional HAT 
family, nuclear receptor coactivator SRC-1 and ACTR are present in mammals but not in 
plants, fungi or other animals [198, 199]. Type B HATs are located in cytoplasm and are 
responsible in acetylation of free histones within cytoplasm, particularly at lysine 5 and 
12 of histone H4, prior to histone incorporation into newly replicated chromatin [200]. 
Type B HATs include hat1p [201], ESA1 [202], tip60 [203] and SAS3 [204].  
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The discovery of cAMP response element-binding (CREB)-binding protein (CBP) and its 
homologue p300, as transcriptional co-activators that have intrinsic histone 
acetyltransferase (HAT) activity, suggest that histones also regulate DNA transcription 
through the recruitment of these co-activators [205]. Study by Janknecht (2002) also 
confirmed this finding by showing that P300/CBP interacts with multiple transcriptional 
regulators, which then facilitates the assembly of the basic transcriptional machinery 
[206]. Numerous studies have reported that synaptic activity in neuronal cells can 
potentially regulate the ability of CBP to function as transcriptional co-activator [207].  
 
Conversely to HATS, histone deacetylases (HDACs) function to remove the acetyl groups 
that may be attached to histones of the nucleosome, which then inhibits access to the 
genes and therefore silencing of genes [208]. So far, 18 different HDACs have been 
identified and divided into three distinct enzyme classes [209, 210]. Class I HDACs, which 
are originally derived from the yeast RPD3, are found in the cell nucleus (HDAC1, 2, 3, 
and 8). In humans, class I HDACs share the same structure and are expressed in the 
nuclei of most cell lines and tissue types [210, 211], whereas class II subgroup (HDAC4, 
5, 7, 9, and 10) are able to shuttle in and out of the nucleus, depending on the cellular 
signals, and are expressed in a small number of cell types [180]. Both class I and II have 
highly conserved catalytic domain but differ in overall composition and size [212]. Class 
III HDACs, share a common ancestry with yeast transcription repressor Sir2 (silent 
information regulator 2) and are composed of Sirtuin (SIRT) proteins 1–7[213]. The most 
recently described HDACs are Class IV, which is represented by HDAC11 [214].  So far, 
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very little is known about its function and regulation. HDAC1 and HDAC2 are often 
associated with large protein complexes such as Sin3, Mi2/NURD and CoREST, which 
demonstrate better deacetylases activity than HDACs components alone [215]. Each 
member of the HDAC family, however, may exhibit a different, individual substrate 
specificity and function in vivo [216] . 
 
Histone methyltransferases (HMTs) are enzymes that catalyze the irreversible histone 
methylation on lysine residues. The HMTs family includes enzyme such as SUV39, which 
is specific for histone H3(K9)[217], SET1c and SET7/9 of H3(K4)[189], SET2 of H3 (K36) 
[218] and DOT1 of H3(K79)[219, 220]. The SUV39, the first HMTs discovered, acts on 
histone H3(K9) and  is localized to transcriptionally silent heterochromatin sites [221]. A 
mechanistic connection between SUV39 and the histone binding protein HP1 
(heterochromatin-associated protein 1) has been established recently [221], and is 
shown to be involved in the formation of heterochromatin [180]. Apart from their ability 
to covalently modify histones, some HMTs have also been shown to directly methylate 
the tumor suppressor, p53. Set9, which specifically methylates H3K4 [222], and has also 
been implicated in the regulation of p53. Methylation of p53 stabilizes and limits its 
localization to the nucleus [186]. More recently, Smyd2, which acts on H3K36 
methylation, has also been directly linked to the regulation of p53 [178]. 
Accumulating evidence implicates the aberrant loss or gain of HMTs activity, which 
often leads to developmental defects and diseases. The HMTs SUV39 family member, 
SUV39H-deficient mice display severely impaired viability and chromosomal instabilities 
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that are associated with an increased tumor risk and perturbed chromosome 
interactions during male meiosis [223], suggesting the importance of HMTs as 
epigenetic regulators for mammalian development. 
 
Histone H3 phosphorylation is catalyzed by the members of Aurora kinase family [224]. 
Immunocytochemical analysis revealed that Aurora-B co-localized with H3, catalyzed the 
phosphorylation of Ser10 from late G2 phase to metaphase and Ser28 from prophase to 
metaphase in mammals [225]. The phosphorylation of Thr(T)3 of histone H3, which is 
catalyzed by kinase haspin, also occurs during mitosis and plays an essential role in 
facilitating condensation and resolution of sister chromatids in late G2 and prophase 
[226]. 
 
1.9.4 Histone post-translational modifications (PTMs) and neurodegenerative 
diseases 
As previously discussed, histone post-translational modifications (PTMs) play significant 
roles in regulating gene activities. Therefore, aberrant pattern of epigenetic regulation 
has been linked to the development of neurodegenerative diseases such as 
polyglutamine diseases (Huntington disease), Rubinstein-Taybi syndrome and AD [215].  
 
During normal neuronal condition, HATs and HDACs, which are responsible for 
regulating acetylation and deacetylation respectively, remain in a state of balance which 
they counteract each other to ensure neurophysiological homeostasis. Such equilibrium 
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(Fig. 1.4A) is responsible for regulating gene expression leading to normal function of 
neuronal cell activity and memory formation [215, 227]. During neurodegenerative 
diseases, the acetylation homeostasis is altered when histone acetylation significantly 
decreases [228], reflecting dysfunctional acetylation-deacetylation apparatus (Fig. 1.4B). 
General loss of acetylating agent, would cause excessive increased in HDAC activity, 
which is then associated with transcriptional repression (Fig. 1.4B). Studies have 
reported that reduction in histone acetylation followed by the increase in HDACs activity 
or DNA methylation is common in many neurodegenerative disorders [229, 230]. 
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Figure 1.4: Neuronal acetylation homeostasis. (i) Weights on the balance represent the 
protein levels of HATs and HDACs. (ii) Enzymatic activity scale represents the activity and 
dark grey areas are physiologically optimal. (A) Under normal neuronal conditions, the 
level and activity of both HATs and HDACs are within their point of balance where they 
counteract each other to maintain internal equilibrium (homeostasis). (B) During 
neurodegenerative disease condition, acetylation homeostasis is altered resulting in the 
loss of HATs level and activity, which balance towards an excessive production of HDACs 
and subsequent increase in deacetylation. 
 
In recent years, the increasing numbers of structurally diverse HDAC inhibitors have 
been identified with the potential to target specific brain regions and in cell-specific 
manner to reverse disorder-specific epigenetic dysregulation [231]. The HDAC inhibitors 
include: short-chain fatty acid (i.e. valproic acid) [232], hydroxamic acid (i.e. SAHA, TSA, 
oxamflatin) [233], cyclic tetrapeptides (i.e trapoxin, apicidin) [234] and benzamide (i.e 
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MS-275) [235]. These HDAC inhibitors are aimed to inhibit its enzymatic activity and to 
remove the repressive blocks from promoters of essential genes and therefore induce 
active gene transcription [215]. The X-ray crystallographic studies showed that this type 
of HDAC inhibitors act as a chelator of zinc ion in the catalytic site of HDACs, which 
therefore block the substrate access to the active zinc ion and subsequently inhibit the 
deacetylation ativity [236].  However, it is still uncertain whether certain 
neurodegenerative disorders are mediated by a specific HDAC. 
 
Aging is also considered as the greatest risk factor for the development of the 
neurodegenerative diseases, where neuronal function declination and gene expression 
alternation could be detected in the aging human brain [237]. Studies have found the 
altered pattern of histone modification in aging cells, such as trimethylation of histone 
H4 at lysine 20, which was increased in kidneys and liver of the old-aged rat [238], and 
the level of H4 acetylation, which was decreased in the rat brain cortical neurons with 
age [239]. Several new methylated sites, such as H3 (K24), H3 (K128) and H2A (R89) 
were also detected in the study of aged mouse brain, however, no functional studies on 
these three sites have been reported [240]. It has been reported that in aging brains, 
most PTM sites were found on histone H3, which has the longest N-terminal tails 
amongst other core histones [240]. These studies suggest the importance of proper 
epigenetic modification in biological activities and neuronal cell development, while the 
altered epigenetic regulation leads to neurodegenerative diseases.  
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1.10 M17 CELL LINE AS A MODEL 
Neurodegeneration is very difficult to study in vivo. Neuronal cells do not regenerate 
and cannot be observed or manipulated without removing them from the patients. For 
these reasons, in vitro models are very important options. An ideal cell line would 
possess similar characteristic as the in vivo neurons, while having the advantage of 
immortalization to ensure continuous supply of cells. Immortalized cells are also 
convenient to handle and experiments can be perfomed during continuous conditions in 
which biochemical process can be easily studied. 
 
Throughout our studies, M17, a neuronal-derived, cell line was used. M17 cells were 
originally isolated from the bone marrow of a two year old male suffering from 
disseminated neuroblastoma (Global Bio-resource Center, 2007). Microscopic analysis 
shows that the cell type indicates a neuronal characteristic; being morphologically small 
in size and dense with triangular-shaped cell bodies. The advantage of this cell line is 
that it is of human origin, and by now, M17 cells constitute a well-studied and defined 
cellular system.  The “in-house” results suggest that M17 cell line is a suitable model for 
studying the effects of zinc and DHA supplementation on bioenergetic function and 
gene regulation of neuronal cells throughout this study. 
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CHAPTER 2 
DHA PROTECTS AGAINST ZINC-INDUCED ALTERATION IN MITOCHONDRIAL 
FUNCTION OF M17 NEUROBLASTOMA 
 
PUBLICATION: 
Sean L. McGee, Nadia Sadli, Shona Morrison, Courtney Swinton and Cenk Suphioglu 
(2010) DHA protects against zinc mediated alterations in neuronal cellular  
bioenergetics. Cell Physiol Biochem. 28(1):157-62. 
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Summary 
 
Aim 
Zinc accumulation in neuronal cells may result in mitochondrial destruction and 
therefore contributes to cellular apoptosis. The aim of the present study was to 
investigate the effect of zinc on mitochondrial function, and how it is affected by DHA 
supplementation in M17 human neuroblastoma cell line. 
 
Methodology 
M17 neuroblastoma cells were treated with zinc (5 μM), DHA (10 μg/ml) or zinc and 
DHA in combination for 48 h. All bioenergetic and mitochondrial function analysis were 
performed using the Seahorse XF24 Extracellular Flux Analyser. 
 
Results 
The results of the first study showed a decrease in cellular oxygen consumption, but not 
glycolytic rate, following chronic zinc exposure, which was specific for neuronal cells. 
This was due to impaired ATP turnover, without any other effects on mitochondrial 
function, and was restored by DHA. These data suggest that zinc disrupts bioenergetics 
at a point distal to the respiratory chain, which is restored by DHA.  
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Conclusion 
This chapter has demonstrated that chronic exposure of M17 neuroblastoma to 
moderate pathological levels of zinc impairs bioenergetics by inhibiting mitochondrial 
ATP turnover. Omega-3 fatty DHA has shown to protect against this effect and this was 
specific for neuronal cell line.  It was also reported that the protective effect of DHA on 
neuronal cells in response to zinc toxicity would include restoration of metabolic 
processes. 
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2.1 INTRODUCTION 
Impaired zinc homeostasis has a profound effect on neuronal cell viability, with zinc 
accumulation being a potent mediator of neuronal cell injury that is implicated in 
neurodegenerative diseases such as AD [21]. The mechanisms by which zinc impairs 
neuronal viability are thought to include impaired bioenergetics [241]. It is not 
surprising that mitochondria represent a target for zinc toxicity, bearing in mind their 
significant role in energy generation and metabolic function such as inhibition of the 
electron transport chain, uncoupling of oxidative phosphorylation, oxidation of 
mitochondrial DNA (mtDNA) and inhibition of mitochondrial DNA synthesis. 
 
As previously described, increased in intracellular zinc accumulation in neuronal cells 
results in cell death. This zinc toxicity occurs due to the specific changes within the cells 
that lead to impairment of intracellular homeostasis and regulation, which can be 
considered as a comprehensive concept of zinc toxicity. It is interesting to note that, in 
all disorders, mitochondria play a key role. There are some critical biochemical 
mechanisms on how mitochondria-induced cell damage may be initiated, namely ATP 
depletion, overproduction of reactive oxygen species (ROS) and reduced oxygen 
phosphorylation, which will be analyzed in this chapter.   
 
Zinc is thought to inhibit a number of metabolic pathways, including glycolysis [242], the 
tricarboxylic (TCA) cycle [243] and the mitochondrial respiratory chain [244]. However, 
much of this data has been gathered from in vitro reactions with purified metabolic 
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enzymes and studies of isolated mitochondria. Therefore, the role of zinc on metabolism 
in intact human neuronal cell lines is not entirely clear. Furthermore, many of these 
studies have used acute supraphysiological levels of zinc to induce bioenergetic 
dysfunction, such that the role of chronic zinc exposure at moderate pathophysiological 
levels on bioenergetics is also unclear. 
 
In this chapter, the aims were to:  1. Determine whether zinc impairs bioenergetics in 
live M17 neuroblastoma cells; 2. Establish whether DHA can protect against any 
alterations in cellular bioenergetics; and 3. Determine whether the effects of zinc and 
DHA on bioenergetics are specific to neuronal cell lines.   
 
2.2 MATERIALS AND METHODS 
2.2.1 Cell culture 
M17 Neuroblastoma cells, obtained from Murdoch Children Research Institute, Royal 
Children Hospital were used in all experiments. M17 cells were originally isolated from 
the bone marrow of a two year old male suffering from disseminated neuroblastoma 
(Global Bio-resource Center, 2007). The M17 cells were grown at 37°C with 5% CO2 with 
100% humidity in Opti-MEM media (a modified MEM (Eagle’s) media) with heat 
inactivated 2.5% Fetal Bovine Serum (FBS) supplementation. To determine whether the 
effects of zinc and DHA on bioenergetics are specific to neuronal cell lines, HaCaT 
human keratinocyte bioenergetics were also examined following chronic zinc exposure. 
HaCaT cell line was maintained in DMEM media supplemented with 10% FBS. Cultures 
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were split when they reached 80-90% confluency and the medium was replaced every 
two days with pre-warmed Opti-MEM or DMEM media.  
 
2.2.1.1      Cell thawing 
Cryopreserved M17 and HaCaT cells in cryovials were removed from liquid nitrogen 
storage and placed into a covered water bath at 37°C until thawed. Quickly, cells were 
pipetted out into a 15 ml tube filled with 10 ml of pre-warmed Opti-MEM or DMEM 
growth media and then transferred to a 75 cm2 culture flask. Cells were then incubated 
at 37°C in a 5% CO2 humidified incubator. After 24 h, culture media was replaced in 
order to remove non-adherent cells and replenish nutrients. 
 
2.2.1.2      Passaging cells 
After old medium was discarded, M17 and HaCaT cells were washed twice with sterile 
phosphate buffered saline (PBS) containing 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4 
and 1.47 mM KH2PO4 (pH.7.3), to remove all traces of growth medium. The cells were 
harvested by adding 3 ml of 0.025% PBS-ethylenediaminetetraacetic acid (EDTA)-Trypsin 
to the culture flask, and solution was gently moved over the cells for 30 sec. The flask 
was placed in the 37°C and 5% CO2 humidified incubator for approximately 1 min. The 
flask was then checked under a microscope to see if the cells had detached from the 
surface of the flask. Non-adherent cells were resuspended in 10 ml medium and 1 ml 
was transferred to a sterile 75 cm2 tissue culture flask. 
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2.2.2  Zinc and DHA treatments 
Docosahexanoic acid (DHA; Sigma Sldrich, MO, USA) stock solution was prepared in 
100% (v/v) ethanol at a concentration of 100 mg/ml and the working solution was 
prepared by adding the stock to the Opti-MEM or DMEM media to get the final 
concentration of 10 µg/ml. DHA stock solution was stored at -20°C and the treatment 
media were prepared fresh before treating the cells. Before starting the experiment, 
DHA-containing media was pre-incubated overnight at 37°C to allow DHA to conjugate 
with media proteins, to allow delivery into cells.  
 
Zinc (in the form of ZnCl2) was added to the media on the day of the experiment to the 
final concentration of 5 μM. The extracellular zinc uptake was previously tested to 
confirm that zinc indeed enters M17 human neuroblastoma cells. It was observed that 
zinc does in fact get into cells as shown by our 65Zn studies [45]. A range of zinc 
concentrations were also tested and anything above 5 μM caused significant death of 
cells, which therefore could not be used for analysis. Therefore, 5 μM was the 
concentration chosen for this study, which also represents the upper physiological 
levels. The growth media was also tested to have no zinc, so the observed results 
obtained in this thesis are indeed zinc effect.  
 
M17 cells were treated with and without zinc (final concentration 5 μM) and DHA (final 
concentration 10 μg/ml) with the addition of anti-oxidant vitamin E (0.05 µM/ml) in 
every DHA treatment groups. 
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2.2.3 Bioenergetics analysis and mitochondrial function tests 
All bioenergetic and mitochondrial function analysis were performed using the Seahorse 
XF24 Extracellular Flux Analyser (Seahorse Bioscience, Billerica, USA).  
 
M17 neuroblastoma and HaCaT cells were seeded into 24-well Seahorse V7 plates at 2.5 
x 104 cells/well. The following day, cells were treated with either vehicle, zinc (5 μM), 
DHA (10 μg/ml) or zinc and DHA in combination for 48 h. Prior to assay, cells were 
washed twice with assay running media (unbuffered DMEM, 25 mM glucose, 1 mM 
glutamine, 1 mM sodium pyruvate), before being resuspended in 675 μl of running 
media. Cells were equilibrated in a non-CO2 incubator for 60 min prior to assay. The 
assay protocol consisted of repeated cycles of 2 min mix, 2 min wait and 4 min 
measurement periods, with oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) measured simultaneously through each measurement period 
by excitation of fluorophores for O2 and H
+. This gives measurement of oxidative and 
non-oxidative metabolism, respectively.  
 
Basal energetics were established after three of these cycles, followed by sequential 
exposure of the ATP synthase inhibitor oligomycin, the proton ionophore 
carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) and the complex III 
inhibitor antimycin A, all to a final concentration of 1 μM. These compounds were 
introduced to the cell media by the Seahorse injection system. Three mix, wait and 
measurement cycles separated each compound injection (protocol is summarized in Fig. 
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2.1). Using these compounds as modulators of mitochondrial function, it is possible to 
determine a number of bioenergetic and mitochondrial parameters, including basal 
respiration, ATP turnover rate, proton leak, maximal and spare respiratory capacity (Fig. 
2.2).  
 
All treatment conditions were analysed as ten replicates, over at least two independent 
experiments and data was pooled to give average values for each treatment. At the 
completion of each assay, the assay plate was frozen at -80oC, prior to determination of 
cell number in each well using the CyQuant kit (Invitrogen, Carlsbad, USA) according to 
manufacturer’s instructions. 
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Figure 2.1: Study design used to measure the bioenergetic and mitochondrial 
functions in M17 and HaCaT cells following zinc and DHA using XF Extracellular Flux 
Analyzer (Seahorse Bioscience).  
Bioenergetic experiment was prepared as illustrated. The treated (zinc, DHA or zinc and 
DHA in combination) and untreated cells were switched from treatment media to assay 
running media. Following baseline measurements, 75 μl of testing compounds 
(Oligomycin, FCCP, and antimycin A) prepared in assay running media in the cartridge 
were introduced to the cell media by the Seahorse injection system. After mixing, OCR 
and ECAR measurements were made.  
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Figure 2.2: Schematic diagram of the mitochondrial function test. Multiple oxygen 
consumption measurements are made basally and after the injection of the ATP 
synthase inhibitor oligomycin, the proton ionophore carbonylcyanide p-
trifluoromethoxyphenylhydrazone (FCCP) and the complex III inhibitor antimycin A. 
From these analyses, basal respiration, proton leak, ATP turnover, spare respiratory 
capacity and maximal respiratory capacity can be calculated. 
 
2.2.4 Statistical analysis 
All values are reported as means ± standard error of the mean (SEM) and were 
evaluated for statistically significant differences using analysis of variance (ANOVA) and 
Tukey post-hoc testing where appropriate. Differences between groups were 
considered statistically significant where p<0.05. 
 
2.3 RESULTS 
2.3.1 Zinc impairs basal cellular bioenergetics in M17 neuroblastoma, which is 
restored by DHA  
The insight into physiological state of cells and alteration of cellular bioenergetic 
function can be studied through measuring the oxygen consumption rate (OCR), an 
indicator of mitochondrial respiration. Here, the extracellular acidification rate (ECAR) 
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was also determined. ECAR is the measure of lactic acid formed during glycolytic energy 
metabolism (in the absence of oxidative phosphorylation).  Cellular OCR and ECAR are 
related to the flux through catabolic pathways used to generate ATP [245]. When the 
OCR is inhibited by toxins or drugs, ECAR would be increased as a result of an increase in 
glycolytic flux, as the cells attempt to recover the mitochondrial ATP lost due to 
inhibition of the electron transport chain, which is associated with reduction in OCR 
[246, 247]. 
 
OCR for M17 neuroblastoma throughout the bioenergetics analysis is shown in Figure 
2.3A. Basal OCR and ECAR are shown in Figure 2.3B. Zinc significantly reduced basal OCR 
when compared with control cells (Figs. 2.3A and 2.3B), without altering basal ECAR (Fig. 
2.3B), which is indicative of mitochondrial dysfunction without non-oxidative 
compensation. Basal OCR was not different in cells exposed to both zinc and DHA, 
suggesting that DHA can protect against zinc-mediated alterations in basal OCR (Fig. 
2.3B). There was no effect of DHA exposure alone on cellular bioenergetics (Fig. 2.3B). 
 
 
 
51 
 
 
 
Figure 2.3: Mitochondrial function and basal bioenergetics in M17 neuroblastoma. 
Oxygen consumption rate (OCR) (A) throughout mitochondrial function testing, and 
basal OCR and extracellular acidification rate (ECAR) (B) of M17 neuroblastoma exposed 
for 48 h to either vehicle (Control), zinc, docosahexaenoic acid (DHA) or zinc and DHA 
together (zinc/DHA). All values are reported as means ± SEM (n=12-15 per group). 
*Denotes significantly different OCR from all other groups (p<0.05).  
 
 
2.3.2  Zinc reduces oxidative ATP turnover, which is restored by DHA 
To further examine why basal oxidative respiration was impaired following zinc 
exposure in M17 neuroblastomas, mitochondrial function in these cells was assessed. 
Zinc decreased oxidative ATP turnover, which was restored with co-exposure of DHA 
(Fig. 2.4A). Both zinc and DHA, either alone or in combination, did not significantly affect 
proton leak (Fig. 2.4B) and maximal respiratory capacity (Fig. 2.4C). However, as zinc 
decreased basal respiration without any significant effect on maximal respiratory 
capacity, zinc increased spare respiratory capacity when compared with all other 
treatments (Fig. 2.4D).  
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Figure 2.4: Mitochondrial function parameters in M17 neuroblastoma. ATP turnover 
rate (A), proton leak (B), maximal respiratory capacity (C) and spare respiratory capacity 
(D) were calculated from oxygen consumption rates of M17 neuroblastomas exposed 
for 48 h to either vehicle (Con), zinc (Zn2+), docosahexaenoic acid (DHA) or zinc and DHA 
together (Zn2+/DHA). All values are reported as means ± SEM (n=10 per group). 
*Denotes significantly different from all other groups (p<0.05).  
 
2.3.3  Zinc and DHA have no effect on cellular bioenergetics in HaCaT keratinocytes  
It has been proposed that due to their relatively high oxidative ATP demand and low 
spare respiratory capacity, neuronal cell bioenergetics, and in turn viability, are 
particularly sensitive to factors that induce mitochondrial dysfunction [248]. To 
determine whether the effects of zinc and DHA on bioenergetics are unique to neuronal 
cell lines, HaCaT keratinocyte bioenergetics following chronic zinc exposure were 
examined. OCR for HaCaT keratinocytes throughout the bioenergetics analysis are 
shown in Figure 2.5A and basal OCR and ECAR are shown in Figure 2.5B. This cell line 
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was used as they too have a relatively high oxidative ATP demand and low spare 
respiratory capacity, which was confirmed in our analysis (Fig. 2.5A). Zinc and DHA had 
no effect on basal keratinocyte bioenergetics (Fig. 2.5B), suggesting that the M17 
neuronal cell line was more sensitive to the effects of zinc and DHA.  
 
Figure 2.5: Mitochondrial function and basal bioenergetics in HaCaT keratinocytes. 
Oxygen consumption rate (OCR) (A) throughout mitochondrial function testing, and 
basal OCR and extracellular acidification rate (ECAR) (B) of HaCaT keratinocytes exposed 
for 48 h to either vehicle (Control), zinc, docosahexaenoic acid (DHA) or zinc and DHA 
together (zinc/DHA). All values are reported as means ± SEM (n=12-15 per group).  
 
2.4 DISCUSSION 
In this chapter, it was observed that chronic exposure of M17 neuroblastoma cells to 
moderate pathophysiological levels of zinc impairs cellular bioenergetics, through 
inhibition of basal respiration. The data showed that ATP turnover was the primary 
parameter of mitochondrial function that was impaired and that there was no 
compensatory response through anaerobic energy sources. This fits with previously 
published data showing that chronic zinc exposure can induce neuronal apoptosis 
through a decline in cellular ATP stores [84, 248], albeit at higher zinc concentrations. 
However, using indirect measures of metabolism, this study found that the primary 
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defect in bioenergetics was glycolysis [248]. There were no alterations in glycolytic rate, 
as measured by cellular proton production, using a bioanalyser that simultaneously 
measures both anaerobic and aerobic flux. While these differences could be due to the 
different analytical methods employed, the concentrations of zinc were also different. 
The present study used moderate pathophysiological zinc concentrations over a 48 h 
period. Importantly, it should be noted that cells were not exposed to zinc in the 60 min 
prior to, and throughout the assays. This suggests that chronic exposure to moderate 
zinc concentrations induces alterations in oxidative metabolism that are not readily 
reversible following withdrawal of zinc.  
 
The analysis of mitochondrial function localized the defect in basal respiration to a 
reduction in mitochondrial ATP turnover. This means that chronic exposure to moderate 
pathophysiological zinc concentrations induces a defect in mitochondrial metabolism 
that is distal to the respiratory chain. It has not been reported so far that zinc inhibits 
ATP synthase directly, or the availability of ADP for conversion to ATP by ATP synthase. 
Indeed, studies using isolated mitochondria with a wide range of zinc concentrations 
and various substrates for metabolism have found inhibition of the respiratory chain, 
most likely at the transfer of electrons between complexes II and III [249, 250]. 
However, zinc has also been found to dissipate the mitochondrial membrane potential 
through regulation of the mitochondrial transition pore [251]. As ATP synthase requires 
the proton gradient of the mitochondrial membrane potential to generate ATP [252], 
this mechanism could account for the impairment of ATP turnover induced by zinc. This 
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mechanism has also been associated with increased production of mitochondrial 
reactive oxygen species, release of cyt c and initiation of apoptosis [241]. These data 
suggest that inhibition of ATP turnover is the primary bioenergetic parameter 
modulated by chronic exposure to moderate pathophysiological concentrations of zinc 
and highlight the complex role that this transition metal has on both normal cell 
function, such as synaptic transmission, and pathological processes, such as initiation of 
apoptosis.  
 
Data from the present study also shows that DHA is able to protect against reductions in 
oxidative ATP turnover. As dissipation of the mitochondrial membrane potential 
appears to be the mechanism by which zinc impairs ATP turnover, it is important to 
speculate on how DHA might protect mitochondrial metabolism. One of the major 
functions of DHA is its incorporation into membranes [253], where they can assist with 
membrane fluidity and function. It is possible that DHA may protect the transition pore 
in response to zinc through its role in membranes. Indeed, it has recently been shown 
that DHA can prevent mitochondrial permeability transition in the heart [254, 255]. 
However, the previous work has showed that DHA may impair cellular zinc uptake [45], 
which could contribute to its protective effects. Nonetheless, the data from the present 
study is the first to show that DHA normalizes cellular bioenergetics in response to 
chronic pathophysiological zinc exposure. As DHA has been shown to protect against 
neuronal apoptosis, part of this protective effect could be ascribed to protection against 
alterations in bioenergetics secondary to altered zinc transport.  
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A final aim of the present study was to examine whether the effects of zinc and DHA on 
cellular bioenergetics were specific to neuronal cells. To address this aim, anaerobic and 
aerobic metabolism in HaCaT keratinocytes was examined. Indeed, it has been proposed 
that neurons are particularly susceptible to apoptosis by insults that perturb 
bioenergetics due to their high ATP demand and relative low spare respiratory capacity 
[248]. HaCaT keratinocytes were used in the present study because of their similar 
properties (Fig. 2.5A). However, the data suggested that these cells were not sensitive 
to zinc mediated alterations in metabolism. A potential explanation for this finding could 
be altered zinc uptake in these cells when compared with neuronal cells. However, 
isolated liver mitochondria are also not sensitive to the effects of zinc on the transition 
pore [256], which could suggest that intrinsic differences in neuronal mitochondria 
make them more sensitive to this effect of zinc. As there was no alteration in 
metabolism following chronic zinc exposure in these cells, DHA had no effect on 
bioenergetics. These data are consistent with the fact that DHA had no effect on 
metabolism independent of zinc in M17 neuroblastoma. Furthermore, this data 
highlights the neuronal reliance on zinc for functions such as synaptic transmission, 
which could in turn make this cell type particularly susceptible to dysregulation of zinc 
homeostasis.  
 
2.5 CONCLUSION 
In conclusion, this study suggests that chronic exposure of M17 neuroblastoma cells to 
moderate pathological levels of zinc impairs bioenergetics by inhibiting mitochondrial 
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ATP turnover. The co-exposure of zinc with DHA protected against this effect and that 
this was specific for neuronal cell lines. It was observed that the protective effect of DHA 
on neurons in response to pathological stimuli also includes modulation of metabolic 
processes. 
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CHAPTER 3 
NEUROPROTECTIVE EFFECT OF DHA AND COENZYME Q10 AGAINST Aβ- 
AND ZINC- INDUCED MITOCHONDRIAL DYSFUNCTION  
IN NEURONAL CELLS 
 
PUBLICATION: 
Nadia Sadli, Colin J. Barrow, Sean Mcgee, Cenk Suphioglu (2011) The effect of DHA 
and  Coenzyme Q10 against Abeta and zinc-induced mitochondrial dysfunction in 
human neuronal cells. Neuropharmacol. (Submitted).   
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Summary 
 
Aim 
This chapter determined whether DHA and Coenzyme Q10 (CoQ10) have independent 
or additive effects against Aβ- and zinc-induced defects in energy metabolism and 
mitochondrial respiratory function in M17 neuroblastoma cells. 
 
Methodology 
M17 neuroblastoma cells treated with Aβ (10 nM), zinc (5 μM), DHA (10 µg/ml in the 
presence of antioxidant vitamin E (0.05 µM/ml)), or CoQ10 (10 μM) alone and in 
combination after 24 h were subjected to following studies:  
1.  Using Seahorse Bioscience XF24 Extracellular Flux Analyzer to measure 
changes in all bioenergetics and mitochondrial function in M17 
neuroblastoma cells. 
2.  To estimate the change in membrane potential (∆Ψm) across inner 
mitochondrial membrane using JC-1 assay.  
3.  Using Amplex red assay to examine the production of intracellular H2O2 in 
M17 cells. 
 
Results 
Study 1: The results demonstrated a decrease in basal mitochondrial respiration in M17 
cells without alteration in glycolytic rate, reduction in ATP turnover rate, uncoupled 
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respiration and maximal respiratory capacity in response to Aβ and zinc. CoQ10 has 
shown to have direct protective effect against Aβ-induced alteration in mitochondrial 
function, while DHA had no significant effect against Aβ toxicity. However, both CoQ10 
and DHA, alone and in combination, have shown to protect against zinc-induced 
mitochondrial dysfunction.  
Study 2: Significant reduction in ∆Ψm  following Aβ was restored by CoQ10. DHA could 
not restore reduction in ∆Ψm caused by Aβ.  On the other hand, CoQ10 alone did not 
have significant effect on ∆Ψm   alteration in response to zinc, suggesting that CoQ10 was 
not directly protective against zinc-mediated alterations in ∆Ψm. 
Study 3: Aβ did not directly affect ROS production whereas zinc significantly increased 
superoxide anion levels. Our results show that combination of DHA and CoQ10 inhibit 
H2O2 production in M17 neuroblastoma cells.  
 
Conclusion  
DHA is specifically neuroprotective against zinc-triggered mitochondrial dysfunction, but 
does not affect Aβ neurotoxicity.  CoQ10 has shown to be protective against Aβ- 
induced alterations in mitochondrial function.  
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3.1 INTRODUCTION 
Previous data has shown that reduced DHA levels in AD brains were associated with an 
increase in intracellular zinc levels [148]. Zinc-mediated brain injury has been implicated 
as a neurotoxin in models of neurodegenerative disease [257]. However, the mechanism 
of zinc toxicity is unknown, but evidence suggests that zinc induces cellular apoptosis 
through inhibition of adenosine triphosphate (ATP) synthesis [21, 241], increase in the 
production of reactive oxygen species (ROS) and eventual loss of mitochondrial 
membrane potential ∆Ψm [241]. Recently, it has been reported that DHA protects 
against zinc-mediated alterations in human neuronal cell bioenergetics and 
mitochondrial function [85]. 
 
AD is characterized by the accumulation of amyloid-beta (Aβ)-containing plaques, 
hyperphosphorylated neurofibrillary tangles, neuronal death and synaptic loss [258, 
259]. Impaired mitochondrial function [259] and  a decrease in membrane potential 
∆Ψm have also been recognized as early events within the Aβ toxicity cascade [260]. 
Coenzyme Q10 (CoQ10), a component of the mitochondrial electron transport chain, is 
well characterized as a neuroprotective antioxidant in human neuronal cells [261], as 
well as in animal models [262] and human trials of AD [263]. CoQ10 has membrane-
stabilizing properties and also plays a vital role in ATP production [264]. Like the omega-
3 FA DHA, CoQ10 levels are decreased with aging [265], and in a number of 
neurodegenerative conditions [266]. 
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Although both DHA and CoQ10 have demonstrated neuroprotection in human neuronal 
cells, it is unclear whether the combined administrations of DHA and CoQ10 have 
additive effects against Aβ- and zinc-induced mitochondrial dysfunction. This chapter 
examined whether combined DHA and CoQ10 could preserve bioenergetics and 
mitochondrial function better than either DHA or CoQ10 alone, in response to Aβ and 
zinc toxicity in human neuronal cells.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Cell culture 
As previously described, human neuroblastoma M17 cells were cultured in Opti-MEM 
media (Invitrogen), supplemented with 2.5% heat inactivated fetal bovine serum (FBS), 
in a humidified incubator at 37oC with 5% CO2. Trypsin/EDTA (0.05%; Gibco) was used 
for trypsinization. 
 
For treatment analysis, the growth media was replaced with experimental media (Opti-
MEM) treated with and without beta-amyloid (Aβ1-42) peptide (final concentration 10 
nM), zinc (final concentration 5 µM), CoQ10 dissolved in acetone (final concentration 10 
μM) and docosahexaenoic acid (DHA) (final concentration 10 µg/ml; Nu Chek Prep Inc, 
Elysian, Mn, USA), in the presence of anti-oxidant vitamin E (final concentration 0.05 
µM/ml).  
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Stock solution of DHA in ethanol was prepared as described in the previous chapter, 
stored at −20°C and pre-incubated in complete growth medium at 37°C overnight to 
allow protein conjugation. CoQ10 was a generous gift from Prof. Colin Barrow, School of 
Life and Environmental Sciences, Deakin University. The synthetic Aβ1-42 peptide was 
purchased from Sigma Aldrich (MO, USA), dissolved in dimethyl sulfoxide (DMSO) and 
stored at -80°C until use. Aβ1-42 peptide was pre-incubated in DMSO at 37°C overnight 
prior to experiments to allow aggregation. Unlike water that would promote a quick Aβ 
aggregation, dissolving Aβ1-42 peptide in DMSO delays the protein aggregation, so pre-
incubation prior experiment is necessary [267]. We initially tested a range of Aβ1-42 
peptide concentrations on mitochondrial function and cell viability. 10 nM Aβ1-42 
peptide in DMSO was chosen as our final concentration, as it induced mitochondrial 
dysfunction without reducing much cell viability. This concentration has previously been 
used to perturb mitochondrial function in other neuronal cell lines [268]. 
 
3.2.2 Seahorse XF-24 metabolic flux analysis 
M17 neuroblastoma cells were cultured in Seahorse XF-24 (Seahorse Bioscience, 
Billerica, USA) plates at a density of 25,000 cells per well. Cells were treated with either 
the control vehicle, Aβ peptide (10 nM), zinc (5 μM), DHA (30 µM), or CoQ10 (10 μM), 
alone and in combination for 24 h, prior to analysis. On the day of analysis, cells were 
changed to unbuffered DMEM (DMEM base medium supplemented with 25 mM 
glucose, 1 mM sodium pyruvate, 1 mM GlutaMax, pH 7.4) and incubated at 37°C in a 
non-CO2 incubator for 1 h. The assay protocol consisted of repeated cycles of 2 min mix, 
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2 min wait and 4 min measurement periods, with oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) measured simultaneously through each 
measurement period by excitation of fluorophores for O2 and H
+. This gives 
measurement of oxidative and non-oxidative metabolism, respectively. Three readings 
were taken after each addition of mitochondrial inhibitor before injection of the 
subsequent inhibitors. The mitochondrial inhibitors used were the ATP synthase 
inhibitor oligomycin (final concentration 1 μM), the proton ionophore carbonylcyanide 
p-trifluoromethoxyphenylhydrazone (FCCP; 1 μM) and the complex III inhibitor 
antimycin A (1 μM). Mitochondrial function parameters were determined using these 
mitochondrial inhibitor compounds as modulators to determine a number of 
bioenergetic and mitochondrial function parameters, including basal respiration, ATP 
turnover rate, proton leak and maximal and spare respiratory capacity.  
 
All treatment conditions were analyzed as ten replicates across 3 plates and data were 
pooled to give average values for each treatment. After the assays, plates were saved 
and protein concentrations for each well were measured. Mitochondrial function 
parameters were determined as described in Chapter 2 [85] and were normalized to 
cellular protein content.  
 
3.2.3 JC-1 assay (inner mitochondrial membrane potential, ∆Ψm) 
Membrane potential across the inner mitochondrial membrane was estimated using the 
fluorescent indicator dye JC-1 (Invitrogen). M17 neuroblastoma cells were seeded into 
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black well/clear bottom 96-well plate at 25,000 cells/well, followed by incubation with 
Aβ (1 nM), zinc (5 μM), DHA (30 µM) or CoQ10 (10 μM) alone and in combination for 24 
h. Stock solution of JC-1 was made up by dissolving JC-1 powder in DMSO at a final 
concentration of 5 mg/ml (kept in -20°C until needed). For a working solution, an aliquot 
of JC-1 dye was diluted 1:25 in OptiMem media. 5 μl of the working solution was added 
to each well and incubated in the dark for 10 min at 37°C. Cells were washed three 
times with 1x phosphate buffered saline (PBS). 100 μl of clear Dulbecco's Modified Eagle 
Medium (DMEM) without serum was then added in each well and fluorescence was 
measured using a FlexStation plate reader and analyzed using SoftMax Pro V5 software 
at 488 nm excitation and 522 nm and 605 nm emissions.  
 
3.2.4 Intracellular reactive oxygen species (ROS) production (Amplex red assay) 
In general, ROS are highly reactive and have short life time [266], which makes them 
difficult to measure directly in biological systems. Therefore, the indirect methods have 
to be used to assess levels of ROS. Amplex Red assay has shown to be a stable and 
sensitive assay, which is based on the non-fluorescent compound N-acetyl-3,7- 
dihydroxyphenoxazine [269].  
 
Amplex red assay is used in this study to fluorometrically determine the Intracellular 
H2O2 production in M17 neuroblastoma cells (Amplex red reagent; Molecular Probes, 
Eugene, OR). Oxidation of Amplex red coupled by horseradish peroxidase (HRP) causes a 
66 
 
reduction of H2O2, which produces the red fluorescent oxidation product, resorufin 
[270]. 
 
To perform this assay, a reaction buffer (1X) was initially prepared from a 5X 
concentrate supplied by the kit, which was comprised of 0.05 M sodium phosphate (pH 
7.4). A 10 mM stock solution of Amplex red was prepared by dissolving Amplex red 
reagent in dimethyl sulfoxide (DMSO). Several stock solutions were prepared according 
to the assay kit instructions. Horseradish Peroxidase (HRP) stock solution (10 U/ml) was 
prepared by dissolving HRP powder in 1X reaction buffer. 
 
M17 neuroblastoma cells were seeded into black well/clear bottom 96-well plates at 
25,000 cells/well (Corning Costar). Concentrations of each treatment were prepared and 
50 μl of each treatment was added to the wells. The reaction was initiated by the 
addition of 50 μl of a working solution that contained 0.1 mM Amplex red reagent and 
0.2 U/ml HRP in 1X reaction buffer. This resulted in a final concentration of 50 μM 
Amplex red reagent and 0.1 U/ml of HRP along with the various treatments in the 
reaction mix with a final reaction volume of 100 μl per well. Using a 544 nm excitation 
and a 590 nm emission, fluorescence was measured kinetically every 30 sec for 30 min 
using a FlexStation II 384 plate reader (Molecular Devices, Sunnyvale, CA). Results were 
analyzed by the Softmax Pro V5 software. 
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3.2.5 Statistical analysis 
Data were presented as mean and standard error of the mean (SEM). When one-way 
ANOVA showed significant differences among groups, Tukey’s post hoc test was used to 
determine the specific pairs of groups that were statistically different. A p -value less 
than 0.05 was considered statistically significant. Analysis was performed with SPSS 16.0 
(SPSS Inc. Chicago, IL, USA). 
 
3.3 RESULTS 
3.3.1 A induces mitochondrial dysfunction in M17 neuroblastoma cells, which is 
restored by CoQ10, but not DHA  
It was shown in this study that Aβ significantly reduced basal OCR when compared with 
control cells without altering basal ECAR (Fig. 3.1A), indicating mitochondrial 
dysfunction without stimulating compensatory glycolysis.  A reduction of OCR in 
response to Aβ treatment was restored by CoQ10 alone and in combination with DHA 
(Fig. 3.1B). However, DHA alone did not directly restore Aβ-mediated alteration in basal 
OCR (Fig. 3.1B). Similar results were observed for mitochondrial respiration due to ATP 
turnover (Fig. 3.1C), uncoupled respiration (proton leak) (Fig. 3.1D) and maximal 
respiratory capacity (Fig. 3.1E).  
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Figure 3.1: Mitochondrial function and basal bioenergetics following Aβ treatment in 
M17 neuroblastoma cells. Representative measurements of the basal OCR/ECAR (A) 
and OCR (B) in M17 cells relative to baseline rates. ATP turnover rate (C), uncoupled 
respiration (D) and maximal respiratory capacity (E) were calculated from oxygen 
consumption rates of M17 neuroblastoma cells treated with beta-amyloid (Aβ) peptide, 
docosahexaenoic acid (DHA) and Coenzyme Q10 (CoQ10), alone and in combination for 
24 h. Values represent the means ± standard error of the mean (SEM) from n=12-15 per 
treatment group. One-way ANOVA (*p<0.05) versus corresponding Aβ-treated cells. 
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3.3.2 Zinc impairs mitochondrial bioenergetic function in M17 neuroblastoma cells, 
which is restored by CoQ10 and DHA, alone and in combination 
To examine whether DHA and CoQ10 could protect against zinc-induced mitochondrial 
dysfunction in M17 neuroblastoma cells, basal OCR, as well as the combined OCR and 
ECAR response together, were measured as described before. This would produce a 
bioenergetic indicative of both mitochondrial respiration and glycolysis, respectively.  
 
There was a significant zinc-induced decrease of the basal mitochondrial respiration in 
M17 cells without alteration in glycolytic rate (Fig. 3.2A). A significant reduction of OCR 
in response to zinc treatment was restored by CoQ10 and DHA, alone and in 
combination (Fig. 3.2B). The decrease in ATP turnover rate (Fig. 3.2C), and maximal 
respiratory capacity (Fig. 3.2E), were also restored by DHA and CoQ10, either alone or in 
combination. A decrease in uncoupled respiration was observed in zinc-treated cells, 
which was restored with either DHA alone or in combination with CoQ10. CoQ10 alone 
did not significantly affect uncoupled respiration (Fig. 3.2D). 
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Figure 3.2: Zinc effect on mitochondrial function and basal bioenergetics in M17 
neuroblastoma cells. Zinc-effect on mitochondrial function and basal bioenergetics in 
M17 cells. Basal OCR/ECAR (A) and OCR (B), as well as ATP turnover rate (C), uncoupled 
respiration (D) and maximal respiratory capacity (E) were calculated based on oxygen 
consumption rates of M17 cells exposed to zinc, docosahexaenoic acid (DHA) and 
Coenzyme Q10 (CoQ10), alone or in combination for 24 h. Values represent the means ± 
SEM from n=12-15 per treatment group. One-way ANOVA, (*p<0.05) versus 
corresponding zinc-treated cells. 
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3.3.3 The neuroprotective effect of DHA and CoQ10 against Aβ- and zinc-induced 
dissipation of the mitochondrial membrane potential ∆Ψm in M17 neuroblastoma cells  
This study measured the mitochondrial membrane potential, which can be used as a 
broad indicator for mitochondrial damage [271]. Furthermore, it has been 
demonstrated that maintenance of the mitochondrial membrane potential is critical for 
neuronal cells survival [272], which also plays a crucial role in the induction of apoptosis 
[273]. 
 
Results showed a significant reduction in ∆Ψm following treatment with Aβ, which was 
restored by CoQ10, alone and in combination with DHA (Fig. 3.3A). DHA alone did not 
restore the reduction in ∆Ψm caused by Aβ. Zinc reduced ∆Ψm, which was restored by 
the addition of DHA, but not CoQ10 (Fig. 3.3B). There were no additive effects of DHA 
and CoQ10 co-incubation, when compared with DHA alone, suggesting that CoQ10 was 
not protective against zinc-mediated alterations in ∆Ψm.  
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Figure 3.3: Aβ and zinc effect on the mitochondrial membrane potential ∆Ψm in M17 
neuroblastoma cells. Aβ and zinc effect on the mitochondrial membrane potential ∆Ψm 
in M17 neuroblastoma cells. Effect of Aβ and zinc on the membrane depolarization of 
M17 cells mitochondria were measured by fluorescence plate reader using JC-1 assay. 
Aβ- (A) and zinc- (B) treated cells showed a reduction in ∆Ψm   compared to the control. 
The cells were exposed to Aβ and zinc with and without DHA and CoQ10 for 24 h. Data 
represent mean and SEM of n=8 per treatment group with asterisks denoting significant 
differences between Aβ or zinc alone and co-exposure of DHA/CoQ10-treated cells. 
One-way ANOVA, (*p<0.05) versus corresponding Aβ or zinc-treated cells. 
 
3.3.4 Zinc-induced mitochondrial dysfunction is associated with increased 
production of reactive oxygen species (ROS)  
Altered ∆Ψm and increase in intracellular levels of H2O2 in neuronal cells are highly 
associated with cell apoptosis and the progression of AD [274]. Since both Aβ and zinc 
have shown to inhibit ATP turn over rate, uncoupled respiration and maximal 
respiratory capacity, their effect on ROS generation was then investigated in M17 
neuroblastoma cells using Amplex red assay. 
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The effects of DHA and CoQ10 against oxidative stress induced by Aβ and 
pathophysiological levels of zinc were evaluated here. It was observed that Aβ did not 
directly affect ROS production when compared to the control cells (Fig. 3.4A), whereas 
zinc induced a small but statistically significant increased in H2O2 levels in M17 
neuroblastoma cells (Fig. 3.4B). However, both DHA and CoQ10, as potent antioxidants 
have shown to reduce H2O2 production (Figs. 3.4A and 3.4B). 
 
 
Figure 3.4: Protective additive effect of DHA and CoQ10 against Aβ and zinc-induced 
H2O2 productions. Neuroprotective effect of DHA and CoQ10 against Aβ- and zinc-
induced H2O2 productions. The Amplex red assay to quantify ROS productions were 
performed in the absence/presence of Aβ, zinc, DHA and CoQ10, alone and in 
combination. Aβ (A) did not affect ROS production, whereas zinc (B) significantly 
increased ROS production in M17 cells. Data are expressed as mean and SEM of n=8 per 
treatment group with asterisks denoting significant differences between Aβ or zinc 
alone and co-exposure of DHA/CoQ10-treated cells. 
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3.4 DISCUSSION 
3.4.1 Aβ and zinc impair basal respiration without alteration in glycolytic rate 
In order to identify the mode of action of both CoQ10 and DHA on Aβ- and zinc-
mediated bioenergetic alterations, oxygen consumption rate in M17 cells was measured 
using the Seahorse extracellular flux analyzer. The results showed a significant reduction 
in basal respiration without alteration in glycolytic rate following exposure to Aβ and 
zinc. This suggests that glycolysis may be the primary defect in bioenergetics.  
 
3.4.2 Aβ and zinc treatments lead to impaired cellular bioenergetics and 
mitochondrial function 
There were significant reductions in basal respiration, mitochondrial ATP turnover rate, 
uncoupled respiration and maximal respiratory capacity following Aβ and zinc 
treatments. This defect of the whole mitochondrial respiratory chain may possibly be 
due to the accumulated dysfunction of one or several mitochondrial chain complexes as 
a result of mitochondrial Aβ, as well as zinc uptake. 
 
Regardless of the dysfunctional features of end-stage cell death, mitochondrial 
membrane permeabilization is frequently the decisive event between cell survival and 
death [260, 275]. Therefore, to further unravel the effect of Aβ and zinc on 
mitochondrial respiratory dysfunction, potential proxy of ∆Ψm and ROS production were 
measured in M17 cells. The data showed the depletion of ∆Ψm following Aβ and zinc 
treatment. This suggests that these Aβ-induced alterations in mitochondrial function 
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may be due to the ability of Aβ to permeabilize cellular membrane and therefore enter 
the mitochondria. A recent study by Pagani and Eckert (2011) has reported the 
deposition of Aβ in the outer and inner mitochondrial membrane [276], which may 
explain the increase in membrane permeability. In the outer membrane, Aβ may be 
present at the site where it could influence the interaction between mitochondria and 
anti-apoptotic marker Bcl-2 [276]. However, in the inner membrane, Aβ may interact 
with the important components of enzymatic activity, metabolic or antioxidant 
mechanisms and therefore inhibit their actions [276]. These interactions of Aβ would 
then affect mitochondrial respiration that would potentially impair cellular metabolism. 
Aβ has been shown to directly inhibit complex IV, but increase in complex III [277], 
which lead to bioenergetic impairment [260]. Taken together, the results suggest that 
following a decrease in ∆Ψm and in uncoupled respiration, which results in a futile 
proton cycle, Aβ exhibit an initial defect in mitochondrial function. This may be caused 
by inhibition of complex IV activity that is translated into a mitochondrial respiration 
deficiency with diminished ATP synthesis, which cannot be compensated by an 
increased activity of complex III.   
 
Apart from decreased ATP turnover rate, maximal respiratory capacity and uncoupled 
respiratory, high physiological level of zinc has been reported to inhibit electron transfer 
[278], which could result in dissipation of  ∆Ψm , as observed in this study. This loss of 
∆Ψm contributes to the decrease in ∆Ψm, which has been reported to be associated with 
release of cytochrome c and apoptosis-inducing factor (AIF) [241]. Aβ did not have much 
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effect on ROS production, whereas zinc significantly increased ROS production, which 
indicates that zinc directly caused oxidative stress in neuronal cells. Zinc has also been 
shown to instigate H2O2 production through tricarboxylic acid cycle (TCA) inhibition 
[279]. It is clear that zinc-mediated neuronal injury requires the mobilization and 
redistribution of zinc in the brain. Therefore, the strategies that prevent excessive zinc 
entry into the cells could ameliorate zinc-mediated cell death [280].   
 
3.4.3 DHA may be directly protective against zinc-induced mitochondrial 
dysfunction, but not towards Aβ toxicity 
Recently, it has been reported that DHA could protect against zinc-altered mitochondrial 
dysfunction in M17 cells [85]. Part of this effect could be due to the neuroprotective 
function of DHA in limiting cellular zinc uptake through decreasing ZnT3 zinc transporter 
expression levels [45, 148], which in turn inhibits zinc toxicity. The data show the ability 
of DHA to restore zinc-induced alteration in ∆Ψm and H2O2 production. It is believed that 
these effects are due to the neuroprotective effect of DHA against zinc-induced ROS 
production caused by oxidative stress, which therefore indirectly stabilizes ∆Ψm.  
 
It was observed that DHA alone did not significantly restore Aβ-mediated defects in the 
mitochondrial parameters assessed in this study. However, co-incubations of DHA in the 
presence of CoQ10 significantly restored Aβ-induced alterations to the same extent as 
CoQ10 treatment alone. These results suggest that DHA alone was not directly 
protective against Aβ-induced mitochondrial dysfunction.  
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3.4.4 The effect of CoQ10 against Aβ- and zinc-induced alterations in mitochondrial 
physiology 
It was observed that CoQ10 could also interact with zinc and restore zinc-mediated 
cellular dysfunction. The finding is supported by a recent study that a decrease in CoQ10 
and increase in zinc levels were observed in chronic obstructive pulmonary disease 
(COPD) patients [281], which probably result from the defense response of organism 
against zinc-mediated inflammation. There is no direct evidence in relation to zinc and 
CoQ10 interactions, however the results suggest that CoQ10 may be neuroprotective 
against zinc-induced mitochondrial dysfunction.  
 
The results have demonstrated that CoQ10 also restores Aβ-induced alteration in 
membrane potential in neuronal cells, which is possibly caused by the ability of CoQ10 
to inhibit the opening of mitochondrial permeability transition pore due to Aβ toxicity 
and therefore stabilize the membrane [261]. CoQ10 has also been reported to inhibit 
the aggregation of Aβ and therefore prevent its toxicity [282]. This may indicate a direct 
anti-amyloidogenic effect of CoQ10 in neuronal cells.  
 
3.5 CONCLUSION 
This study presents a novel finding on the effects of CoQ10 and DHA against Aβ- and 
zinc- mediated bioenergetic alterations in M17 human neuroblastoma cells. The results 
have shown that CoQ10 may have direct effect on Aβ-induced alterations in 
mitochondrial function, while DHA has no significant effect against Aβ toxicity. On the 
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other hand, DHA, due to its direct molecular interaction with zinc [45, 148, 152], may 
protect against zinc-mediated mitochondrial dysfunction. CoQ10 however has also 
shown to restore zinc-induced mitochondrial alteration to the same extent as DHA, 
suggesting the neuroprotective effect of CoQ10 against zinc toxicity. 
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CHAPTER 4 
THE EFFECT OF ZINC AND DHA ON HISTONES H3 AND H4 EXPRESSIONS 
LEVELS IN HUMAN NEURONAL CELLS 
 
PUBLICATION: 
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Lesheim, Andrew Sinclair, Leigh Ackland (2010) Zinc and DHA have opposing effects on 
the expression levels of histones H3 and H4 in human neuronal cells.  Br J Nutr. 
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Summary 
 
Aim  
Zinc and DHA have putative neuroprotective effects and these two essential nutrients 
are known to interact biochemically. This chapter aimed to identify novel protein 
candidates that are differentially expressed in human neuronal cell line M17 following 
zinc and DHA that would explain the molecular basis of this interaction.  
 
Methodology 
Two-dimensional gel electrophoresis and mass spectrometry were applied to identify 
major protein expression changes in the protein lysates of human Ml7 neuronal cells 
that had been grown in the presence and absence of zinc and DHA. Proteomic findings 
were further investigated using Western immunoblot and real-time PCR analysis. Four 
protein spots, which had significant differential expression were identified and selected 
for in-gel trypsin digestion followed by matrix-assisted laser desorption ionization mass 
spectrometry analysis. The resultant peptide mass fingerprint for each spot allowed 
their respective identities to be deduced. 
 
Results 
Two human histones variants H3 and H4 were identified as differentially expressed 
proteins following zinc and DHA. Both H3 and H4 were down-regulated by zinc in the 
absence of DHA (zinc effect) and up-regulated by DHA (DHA effect) in the presence of 
81 
 
zinc (physiological condition). These proteomic findings were further supported by 
Western immunoblot and real-time PCR analysis using H3- and H4-specific monoclonal 
antibodies and oligonucleotide primers, respectively.  
 
Conclusion 
The results suggest that dietary zinc and DHA cause a global effect on gene expression, 
which is mediated by histones. Such novel information provides possible clues to the 
molecular basis of neuroprotection by zinc and DHA that may contribute to the future 
treatment, prevention and management of neurodegenerative diseases. 
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4.1  INTRODUCTION 
It was shown that the alteration in both DHA and zinc homeostasis are the key features 
of neurodegenerative disorders [148, 283, 284]. Previous study has demonstrated the 
link between a reduction of DHA in the diet of rats and over-expression of ZnT3, a 
transmembrane protein involved in transport of zinc into synaptic vesicles [148], 
suggesting a direct interaction between DHA and zinc. Although zinc is an important 
nutrient in high concentrations zinc is toxic and it induces formation of amyloid plaques 
and brain cell death, which are significant features of aging-related neurodegenerative 
processes like AD [285]. Since low levels of DHA and high levels of synaptic zinc are 
commonly seen in AD brains, these results suggest a likely synergy between zinc and 
DHA in AD pathophysiology.  
 
Although previous data has shown a relationship between DHA and zinc homeostasis 
[45], the basis of the molecular interaction in genomic level has not been elucidated. 
Therefore, this chapter aimed to investigate the novel candidates that are differentially 
expressed in response to zinc and DHA in human neuronal cell line M17. Here, the 
results show for the first time that zinc and DHA affect the expression levels of histones 
H3 and H4 in the human neuronal cell line M17.  
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4.2 MATERIALS AND METHODS 
4.2.1 Cell culture 
Human neuroblastoma M17 cells were maintained in Opti-MEM media as previously 
described. The cultures were growth at 37oC in humidified air containing 5% CO2. Cells 
were treated with zinc (5μM), DHA (10 μg/ml in the presence of 0.05 µM/ml antioxidant 
vitamin E) or zinc and DHA in combination for 48 h. The cell treatments were prepared 
as described previously.  
 
4.2.2 Preparing cell lysates 
M17 cells were seeded at a density of 1 x 106 cells/75cm2 flasks and grown in media 
supplemented with and without zinc and DHA. After 48 h incubation, the cells were 
harvested, centrifuged at 1,000 x g for 5 min and pellets were resuspended in PBS.  Each 
sample was then divided into aliquots, centrifuged at 14,000 x g for 5 min and cell 
pellets were stored at -80°C until needed for analysis. 
 
4.2.3 Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)  
Cell pellets were resuspended in ZOOM protein solubilizer 1 lysis buffer (Invitrogen, CA, 
USA), disrupted by passing through a 21-gauge needle and sonicated by using a 
Microsone Ultrasonic cell disrupter (Misonix Incorporated, NY, USA), following the 
manufacturer’s instructions. Samples were then centrifuged at 14,000 x g for 20 min at 
4°C and stored in small aliquots at -80°C until needed for analysis. 
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Quantification of the protein concentration in cell lysates were performed using Quant-
ITTM Protein Assay Kit (Invitrogen) and Qubit™ Fluorometer, following the 
manufacturer’s instructions. 
 
Isoelectric focusing (first dimension) was performed using pH 3-12 IPG strips 
(Invitrogen). Before the second dimension SDS-PAGE separation, IPG strips were 
reduced and alkylated with a solution containing 0.1 M Tris-HCL (pH 6.8), 20% glycerol, 
10% SDS ,10% reducing agent β-Mercaptoethanol and a trace of Bromophenol Blue.  
Additionaly, the reduction step contained 1% DTT and the alkylation step 125 mM 
iodoacetamide. Proteins were separated according to their molecular weight (second 
dimension) on 4-20% Tris-Glycine ZOOM gels (Invitrogen) following the manufacturer’s 
instructions. Following 2D electrophoresis, gels were fixed in 50% methanol and 7% 
acetic acid for 30 min, which then stained with SYPRO Ruby protein gel stain (Invitrogen) 
and incubated overnight at room temperature. The following day, gels were washed 
with 10% methanol and 7% acetic acid for 30 min. Gel images were captured using 
Fujifilm LAS-300 UV transilluminator (Fujifilm, VIC, Australia) to visualize protein spots. 
 
4.2.4 Protein identification (Mass spectrometry analysis) 
Proteins of interest were excised from each gel by automated robotic cutter and placed 
into sequential wells in a 96 well format plate and subjected to two rounds of destaining 
with 25 mM ammonium bicarbonate and dehydration with 50% acetonitrile. The gel 
plugs were then fully dehydrated at 37oC prior to digestion with porcine trypsin for 16 h 
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at 37oC. Digestion products were released from the gel plugs by sonication and acidified 
using 1% Trifluoroacetic acid (TFA). The peptides were then purified using a C18 zip tip 
according to the manufacturer's instructions (Varian, CA, USA) and eluted on to the ABI 
mass spectrometry target in α-cyano-4-hydroxycinnamic acid (HCCA) matrix. The 
resulting peptides were then analysed by Matrix-Assisted Laser Desorption Ionisation - 
Time of Flight/Time of Flight (MALDI-TOF/TOF) mass spectrometry using the ABI 4700 
Proteomics Analyser (Applied Biosystems Inc (ABI), CA, USA). Samples were initially 
analysed in single MS mode to determine the peptide mass fingerprint of the sample. 
The ten most intense peptide peaks were then isolated, fragmented and analysed in 
tandem MS/MS mode to determine de novo amino acid sequence of the peptides 
selected. A combined protein score for the peptide mass fingerprint and ten most 
intense peptides was obtained using the Mascot bioinformatic search engine 
(Department of Primary Industries, VIC, Australia) to search the NCBInr, Homo sapiens 
database, mass tolerance 100 ppm and oxidation as a variable modification. Proteins 
were identified via their peptide mass fingerprint and deduced amino acid sequence 
determined by single MS and tandem MS/MS, respectively. Protein identity was only 
reported for samples that gave a significant (P<0.05) molecular weight search (MOWSE) 
score. 
 
4.2.5 Western Immunoblot analysis 
Cell lysates (described above) were resolved on 15% SDS-PAGE gels following our 
established techniques [286]. A molecular weight marker (Bio-Rad Laboratories, 
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Hercules, CA, USA) was employed for the confirming of protein transfer and the 
molecular weight orientation. For the electro-blotting of proteins onto a nitrocellulose 
membrane (Pall Life Science, FL, USA), a Tris-glycine “wet” electrophoretic transfer 
system containing 20% methanol was used (25 mM Tris, 192 mM glycine, and 20% 
methanol). The use of methanol was shown to increase the binding capacity of 
nitrocellulose for proteins [287]. After transfer of the proteins from the gel to the 
membrane, the remaining protein-binding sites on the membrane were blocked for 1 h 
at room temperature with 1% (w/v) non-fat skim milk in Tris buffered saline (TBS; 50 
mM Tris.HCl, pH 7.4 and 150 mM NaCl) to avoid non-specific binding of the antibodies 
or detection reagents in subsequent steps. Immunoblots were then incubated overnight 
at 4°C with 1/1,000 dilution of monoclonal mouse anti-human H3 and H4 antibodies 
(Abchem, NSW, Australia). After intensive washing procedure with TBS, 1 h incubation 
was carried out with horseradish-peroxidase-conjugated 1:4,000 dilution secondary 
antibody for 2 h at room temperature followed by another wash with TBS. Antibody 
binding proteins were visualized using Immobilan Western Chemiluminesence HRP 
substrate (Millipore Corporation, CA, USA) according to manufacturer’s instructions.  
 
Developed membranes were stripped with Re-Blot Plus stripping solution (Chemicon, 
Temecula, CA) and were re-probed for β-actin using mouse anti-β-actin (Sigma Aldrich) 
primary antibody (1/5,000 dilution) followed by anti-mouse HRP antibody (Chemicon 
International) and developed as described above. Membranes were photographed using 
87 
 
Fujifilm LAS-300 (Fujifilm, Tokyo, Japan), and the subsequent densitometry analysis of 
bands was done with the Fujifilm Multi Gauge V3.0 program (Fujifilm, Tokyo, Japan). 
 
4.2.6 RNA isolation and Real-time PCR analysis 
M17 Cells treated with and without zinc and DHA (as described above) were harvested 
by centrifuging cell suspension at 1,000 x g for 5 min at 4°C. Supernatant was decanted 
and all remaining media was removed. Total RNA was isolated from cell pellers using 
RNeasy Mini-kit (Qiagen, Clifton Hill, Victoria, Australia). Cells were disrupted by adding 
350 µl buffer RLT containing 1% β-mercaptoethanol and mixed thoroughly by vortexing 
vigorously. 350 µl 70% ethanol was added, mixed thoroughly by pipetting. The sample 
was applied to an RNeasy mini column placed in 2 ml collection tube. The tube was 
closed gently and centrifuged for 15 sec at 12,000 rpm. The flow-through was discarded. 
700 µl buffer RW1 was pipetted into RNeasy mini column and again centrifuged for 15 
sec at 8,000 x g to wash. The flow-through was discarded. 500 µl buffer RPE was 
pipetted onto the RNeasy column. The tube was closed gently and centrifuged for 15 
sec at 8,000 x g. The flow-through was discarded. Another 500 µl buffer RPE was added 
to the RNeasy column. The tube was closed gently and centrifuged for 2 min at 8,000 x 
g. The RNeasy column was placed into a new 2 ml collection tube and centrifuged at 
8,000 x g for 1 min. To elute, the RNeasy column was transferred into a new 1.5 ml 
collection tube. 50 µl RNase –free water was pipetted directly onto the RNeasy silica-gel 
membrane. The tube was closed gently and centrifuged for 1 min at 8,000 x g.  
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Because this isolated RNA would be employed in real time -PCR, therefore DNA 
contamination in RNA template was not permitted. Even though RNeasy silica-
membrane technology can eliminate most of DNA but DNase treatment still applied to 
ensure completely removal of DNA.  
DNase treatment was undertaken according to instructions included with the Ambion 
(Austin, Texas) DNA-free™ kit. Briefly, a master mix of 0.1 volume of 10 x DNase I buffer 
and 1 μL rDNase I per sample was made up and was added to each sample. The samples 
were mixed and incubated for 20-30 min at 37°C. DNase inactivation reagent (0.1 
volume) was added to each sample which was then thoroughly mixed. Samples were 
incubated for 2 min at room temperature and centrifuged at 10,000 x g for 
approximately 1.5 min. Aqueous RNA was transferred into a new tube and stored at -
70°C until required. The RNA concentration and purity was spectrophotometrically 
measured on Nanodrop ND-1000 (NanoDrop Technologies, DE, USA). 1 μg of total RNA 
was reverse transcribed by using High-Capacity cDNA Reverse-Transcription kit (Applied 
BIosystem, Foster City, CA, USA). mRNA expression of Histone H3 and H4 were 
quantified, in triplicate by on 7500-Real Time PCR System (Applied BIosystem, Foster 
City, CA, USA) using 1 x SYBR green PCR master mix (Applied Biosystem, Warrington, UK) 
and specific primers to human histone H3 and H4.  Primers were designed using Primer 
Express (Applied Biosystems, Foster City, CA). Target sequences used were sourced from 
the Entrez Nucleotides Database (http://www.ncbi.nlm.nih.gov). Potential cross 
reactivity of primers with other mRNA species was assessed by using the Basic Local 
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Alignment Search Tool (BLAST) and the Entrez Nucleotides Database. Primers were 
purchased from Geneworks and were designed as follows: 
GENE FORWARD (5’       3’) REVERSE (5’       3’) 
Histone H3 AATCGACCGGTGGTAAAGCA TTGCGAGCGGCTTTTGTA 
Histone H4 TTATGAGGAAACTCGCGGAGTG TGGCTGTGACTGTCTTGCGTT 
 
The housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used 
as the endogenous control. Expression levels for each sample were calculated using ∆Ct 
method where the data were normalized by determining the difference in Ct values 
between H3 or H4 genes and GAPDH.  The fold change was calculated as 2-∆∆Ct where 
the ∆∆Ct is the difference between the treated ∆Ct and control ∆Ct. Significance 
(P<0.05) was tested by the Student’s t-test.  
 
4.2.7 Statistical analysis 
The level of histone H3 and H4 protein and gene expressions in M17 cells treated with 
zinc with and without DHA were compared by Student’s t-test using Statistical Package 
for the Social Sciences software (SPSS 16.0). *P < 0.05 was considered statistically 
significant. 
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4.3 RESULTS 
4.3.1 Proteomic analysis of human neuronal cells with and without zinc and DHA 
The change of M17 neuroblastoma cells proteome treated with and without zinc and 
DHA was assessed using proteomic approaches, including 2D-electrophoresis and 
Western immunoblotting to identify novel proteins that are differentially expressed in 
response to zinc and DHA. 
The effect of zinc alone on M17 cells proteins (Fig. 4.1) was first investigated. Many 
protein spots were significantly increased following treatment of zinc (Fig. 4.1B). There 
were two basic spots at around 11 and 15 kDa which showed a significant reduction in 
protein amounts (S1 and S2 in Fig. 4.1A) and these were chosen for mass spectrometry 
analysis. 
 
The effect of DHA on M17 cells in the presence of zinc was also investigated by 2D-
analysis (Fig. 4.2). A significant reduction in the number and level of protein spots with 
DHA treatment were observed, however the protein levels of two spots were 
significantly increased with the DHA treatment (S3 and S4 in Fig. 4.2B). These two spots 
occupied similar isoelectric point (pI) and molecular mass as those seen in zinc deficient 
cells (S1 and S2 in Fig. 4.1A). These spots were therefore selected for mass spectrometry 
analysis. 
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Figure 4.1: Effect of zinc on protein expression in M17 neuroblastoma cells.  
2D image of the proteome expression of M17 cells grown in the absence of DHA without 
zinc (control) (A) and with zinc (final concentration of 5 μM) (B), highlighting proteins 
selected for identification. Proteins were separated first according to their pI using pH 3-
12 IPG strips. In the second dimension, proteins were separated according to their 
molecular weight using 4-20% pre-cast SDS-PAGE gel. Five microlitres of molecular mass 
markers (Mr) were run concurrently and Gels were stained with SYPRO Ruby staining. 
Arrows indicate protein spots of significant difference which were subjected to mass 
spectrometer analysis (S1, S2). 
 
 
 
 
 
(A). Control (-DHA -zinc) 
(B). Zinc treatment (-DHA +zinc) 
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Figure 4.2: Effect of DHA on protein expression in M17 neuroblastoma cells. 
Proteome expression of M17 cells grown in the presence of zinc (final concentration of 5 
μM) without DHA (A) or with 10 μg/ml DHA (B). Five microlitres of molecular mass 
markers (Mr) were run concurrently and gels stained with SYPRO Ruby staining. Arrows 
indicate protein spots of significant difference that were subjected to mass 
spectrometer analysis (S3, S4). 
 
 
 
(B). 
(A). Zinc treatment (+ zinc -DHA) 
(B). Zinc and DHA treatment (+ zinc +DHA) 
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The protein spots S1, S2, S3 and S4 (Figs. 4.1 and 4.2, respectively) were precisely 
excised by an automated robotic cutter, in-gel digested by trypsin and the peptide 
fingerprints subjected to mass spectrometric analysis. Upon Homo sapiens NCBI 
database searches, the identities of the spots were revealed with a score of 100% match 
(Table 4.1). Both S1 and S3 spots were identified as human histone H3 (pI 11.1, 15.3 
kDa) while spots S2 and S4 were identified as human histone H4 (pI 11.4, 11.4 kDa) 
matching perfectly with the pI and molecular mass observed in the 2D gels (Figs. 4.1 and 
4.2, Table 4.1). 
 
2D 
PROTEIN 
SPOT 
PROTEIN SPECIES ACCESION 
NO.  
PROTEIN 
Mr 
PROTEIN 
pI 
PROTEIN 
SCORE (%) 
S1 H3histone, 
family 3A 
Homo 
sapiens 
gi|51859376 15346.5 11.14 100 
S2 HIST2H4 
protein 
Homo 
sapiens 
gi|124504316 11370.4 11.36 100 
S3 H3histone, 
family 3A 
Homo 
sapiens 
gi|51859376 15346.5 11.14 100 
S4 HIST2H4 
protein 
Homo 
sapiens 
gi|124504316 11370.4 11.36 100 
 
Table 4.1: Protein identification by mass spectrometry. Protein spots S1-S4 were 
excised from each gel by automated robotic cutter and subjected to trypsin digest 
followed by mass spectrometry analysis and submission of peptide fingerprints to Homo 
sapiens National Center for Biotechnology Information (NCBI) database searches. 
Proteins were identified via their peptide mass fingerprint and deduced amino acid 
sequence determined by single MS and tandem MS/MS, respectively. pI = isoelectric 
point; Mr = molecular mass. 
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To validate the proteomic findings, human histones H3 and H4 protein and mRNA levels 
were investigated using Western blotting and real-time PCR analysis, respectively.  
 
4.3.2 Western blot analysis of human histone H3 and H4 
Using monoclonal antibodies specific to human histone H3 and H4, the same M17 total 
protein cell lysates as used in 2D analysis were subjected to Western blot analysis. In the 
absence of DHA, both histones H3 and H4 were down-regulated upon zinc treatment 
(zinc effect) (Figs. 4.3A and 4.4A), correlating with the 2D results (Fig. 4.1). In the 
presence of zinc and DHA (DHA effect), both histone H3 and H4 were up-regulated (Figs. 
4.3A and 4.4A), again correlating with the 2D results (Fig. 4.2). To ensure that the 
observed changes in protein levels were not attributed to unequal protein loading of the 
wells of the gels, the same blots were probed with β-actin house-keeping protein, and 
this showed that there was equal protein banding intensities (Figs. 4.3B and 4.4B). 
Furthermore, densitometric analysis of the protein bands in relation to β-actin indicated 
significant difference in expression levels (Figs. 4.3C and 4.4C).  
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(A). 
 
 
(B).  
 
 
(C). 
 
 
Figure 4.3: Histone H3 protein expression levels following zinc and DHA treatments in 
M17 neuroblastoma cells. Western blot analysis of H3 (A) and β-actin (B) expression in 
M17 cells grown in media supplemented with (+) or without (-) zinc (final concentration 
of 5 μM) and with (+) or without (-) 10 μg/ml DHA. (C) Densitometric analysis in arbitrary 
units (AU) are shown as means, with standard error represented as vertical bars. n=3,  
*P < 0.05. Molecular mass protein markers (Mr) are indicated on the left of each gel. 
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(A).  
 
 
(B).  
 
 
(C). 
 
 
Figure 4.4: Histone H4 protein expression levels following zinc and DHA treatments in 
M17 neuroblastoma cells. Western blot analysis of H4 (A) and β-actin (B) expression in 
M17 cells grown in media supplemented with (+) or without (-) zinc (final concentration 
of 5 μM) and with (+) or without (-) 10 μg/ml DHA. (C) Densitometric analysis in arbitrary 
units (AU) are shown as means, with standard error represented by vertical bars. n=3, 
*P < 0.05. Molecular mass protein markers (Mr) are indicated on the left of each gel. 
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4.3.3 Real-time PCR analysis of human histones H3 and H4 
In order to investigate if changes in protein levels of histone H3 and H4 correlated with 
mRNA levels in M17 cells treated with and without zinc and DHA, real-time PCR analysis 
was performed. In the absence of DHA, both histones H3 and H4 showed significant 
down-regulation of mRNA levels in response to zinc treatment (-1.8 and -1.5 fold 
difference between treatment and control, respectively) (Fig. 4.5). In the presence of 
zinc, both histone H3 and H4 demonstrated significant up-regulation of mRNA levels in 
response to DHA (0.8 and 1.2 fold difference between treatment and control, 
respectively) (Fig. 4.5). Taken together, the changes observed in mRNA levels of histone 
H3 and H4, with zinc and with and without DHA (Fig. 4.5), correlated well with the 
changes observed in protein levels (Figs. 4.1, 4.2, 4.3 and 4.4). 
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(A). 
 
 
 
(B).  
 
 
 
 
Figure 4.5: Relative mRNA expression levels of histone H3 and H4 in M17 
neuroblastoma cells treated with and without zinc and DHA. Real-time PCR analysis of 
H3 (A) and H4 (B) expression in M17 cells treated with and without zinc and DHA. 
Negative values (less than zero) refer to down-regulation/reduction and positive values 
(more than zero) refer to up-regulation/increase in fold difference of histone H3 and H4 
mRNA between the treatments. Fold difference is the difference in mRNA levels 
between – and + zinc (zinc effect) and – and + DHA (DHA effect). Data are shown as 
means + SE, n=3. All statistical analysis was tested against a probability value (P) of  
< 0.05, compared to control (-DHA/-Zinc or -DHA/+Zinc).  
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4.3.4 Sequence analysis 
Having demonstrated the effects of zinc and DHA on H3 and H4 protein and mRNA 
levels in M17 human neuronal cells, the sequences of these histones were then 
analyzed to reveal molecular details that would help to understand the connection 
between the histones H3/H4, zinc and DHA. 
Comparison of nucleic and amino acid sequences between human H3 and H4 show 
minimal sequence identities. H3 and H4 have only 44.8% nucleic acid identity and only 
20.6% amino acid identity (Table 4.2). It is interesting to note that there is 100% amino 
acid identity between human and mouse H3 and H4, such that similar effects of zinc and 
DHA on histones could be predicted in the mouse. 
 
AA 
NA 
H3 H4 
H3 100% 20.6% (34.8%) 
H4 44.8% 100% 
 
Table 4.2: Nucleic (NA) and amino (AA) acid identity and similarity (italic values in 
brackets) between human histones H3 and H4. Nucleic and amino acid sequences were 
analysed by EMBOSS pairwise alignment algorithms on the EMBL-EBI database 
(http://www.ebi.ac.uk/Tools/emboss/align/).  
 
 
Since zinc had an effect on the expression levels of histone H3 and H4, 4,000 bp 
upstream from the start codon of these histones were searched for transcription 
binding motifs. Indeed, metal responsive elements (MRE) were identified in both H3 and 
H4 (Table 4.3). Both histones H3 and H4 are present on two different chromosome 
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clusters (eg. Clusters 1 and 2). For histone H3, one MRE is present in cluster 1 (located 
2610 base pairs upstream from the start codon) while two MREs are present in cluster 2 
(located 743 and 919 base pairs upstream from the start codon) (Table 4.3). For histone 
H4, two MREs are present in cluster 1 (located 1405 and 1995 base pairs upstream from 
the start codon) while no MRE was detected in cluster 2 (Table 4.3). 
 
HISTONE TRANSCRIPTION 
BINDING MOTIF 
MRE TGCRCNC 
CHROMOSOME 
LOCATION 
NA POSITION FROM 
START CODON 
 
H3 
TGCGCGC 6p21.3 
Cluster 1 
-2610 bp 
TGCGCGC, TGCGCGC 1q21 
Cluster 2 
-743 bp, -919 bp 
 
H4 
TGCACCC, TGCACAC 6p21.3 
Cluster 1 
-1405 bp, -1995 bp 
X 1q21 
Cluster 2 
X 
 
Table 4.3: Metal response elements (MRE), as transcription binding motifs, in histone 
H3 and H4. Metal response elements (MRE), as transcription binding motifs, in H3 and 
H4 with their respective chromosome locations and nucleic acid (NA) position upstream 
from the start codon in base pairs (bp) identified from NCBI database searches 
(http://www.ncbi.nlm.nih.gov/sites/entrez). X – not present; R – bases A or G; N – bases 
G, A, T or C. 
 
 
4.4 DISCUSSION 
4.4.1 Zinc and DHA cause global effect on gene expression mediated by histones 
Given what is known in regards to the protective effect of DHA [144, 288] and the 
deleterious effects of its deficiency on neuronal health [283, 289] basic questions 
remain about the underlying mechanisms. Previous studies have indicated a possible 
molecular interaction between zinc and DHA [45, 148]. Although an essential nutrient 
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[84, 290], an elevation of [Zn2+]i may become neurotoxic [84], thus contributing to the 
formation of amyloid plaques and cell apoptosis which are significant features of aging-
related neurodegenerative processes such as AD [285, 291].  
This study was conducted to answer questions about possible mechanism behind 
molecular interaction between zinc and DHA, which is based on the well established 
data that both zinc and DHA play an important role in neuroprotection, perhaps even 
synergistically, by modulating gene and protein expression. In this study, histones, 
particularly H3 and H4, were discovered as proteins that were differentially expressed as 
a result of zinc and DHA supplementation, which provides evidence to support this 
hypothesis. 
 
In the study reported here, both H3 and H4 were significantly down-regulated by zinc in 
the absence of DHA (zinc effect) and significantly up-regulated in M17 human neuronal 
cells following DHA treatment in the presence of physiological zinc levels (DHA effect). 
This is the first report showing that zinc and DHA regulate the expression levels of 
histones H3 and H4 in the M17 human neuronal cell line. 
 
4.4.2 Possible mechanisms on the Effect of zinc and DHA on H3 and H4 expression  
Both H3 and H4 possess multiple metal response elements upstream of their start 
codons, which suggest that the transcription of genes is under the control of zinc, 
possibly through metal binding transcription factors. Thus, the results indicate that zinc 
may inhibit/repress the transcription of histone H3 and H4 in M17 human neuronal 
102 
 
cells, resulting in lower histone protein levels, as observed in this study. Indeed, there 
are emerging studies that show a role for zinc-mediated transcriptional repression, 
rather than activation, through MREs [292]. It is has been reported that inhibition of 
DNA synthesis terminates histone protein synthesis indicating that histone synthesis and 
DNA synthesis are very tightly linked [293]. Although not investigated here, it is possible 
that zinc may also affect DNA synthesis and thereby result in the termination of H3 and 
H4 synthesis in M17 cells. Conversely, it was observed that DHA up-regulates expression 
levels of both H3 and H4 and abolishes the effect of zinc suggesting that there is an 
interaction between zinc and DHA in these neuronal cells. The mechanism for this 
interaction is not clear, however the end result is that zinc and DHA together may 
increase DNA synthesis.  
 
These results are supported by previous studies, which found that zinc affects histone 
expression in the mouse thymus [294]. It has been demonstrated that the expression of 
a number of transcription/translation related factors, including H3 histone family 3A 
protein were influenced by zinc, showing that dietary zinc can also alter gene expression 
levels. In other study, rats fed a DHA-enriched diet for two months displayed many 
alterations in gene expression, among which H3 histone, family 3B (H3f3b) was 
identified [295]. The results obtained in this chapter are supported by other data in the 
literature, suggesting that zinc and DHA alter histone subunit expression, which in turn 
may alter the expression of many other genes. On a different note, effects of both zinc 
and DHA on histone expression may result from effects on the cell cycle. However, in 
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M17 human neuronal cell line, cells will be at different stages of the cell cycle and cell 
cycle effects cannot be ascertained.     
 
Figure 4.6 summarizes  the key findings from this chapter based on the observation that 
Zinc and DHA cause global effect on gene expression mediated by histones. Zinc inhibits 
transcription of histone H3 and H4 in M17 cells and therefore reduces histone protein 
and mRNA levels.  Zinc may also affect DNA synthesis, which result in termination of H3 
and H4 synthesis hence gene regulation. This leads to cellular apoptosis and 
neurodegenerative diseases (ND). DHA on the other hand, may induce DNA synthesis, 
through an increase in the level of histones H3 and H4. DHA may contribute to 
minimizing the onset of neurodegenerative disease through maintaining the integrity of 
DNA and histones H3 and H4 synthesis.  
 
 
Figure 4.6: Diagrammatic representation of key finding and potential outcomes.  
Zinc reduces Histone H3 and H4 expression levels, which then affect in reduction in gene 
regulation and therefore increase in apoptosis and neurodegenerative disease. On the 
other hand, DHA in the presence of zinc increases Histone H3 and H4 expression levels 
which also increase gene regulation and neuroprotection, therefore reduce the onset of 
neurodegenerative disease. ND = Neurodegenerative Diseases. 
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4.5 CONCLUSION 
This chapter has shown for the first time that zinc and DHA alter expression of histone 
H3 and H4 in the M17 human neuronal cell line. This suggests that expression of H3 and 
H4 may be negatively controlled by zinc via multiple MRE [296]. Conversely, DHA may 
play a role in the up-regulation of H3 and H4 in nucleosome formation and gene 
expression. Under normal physiological zinc conditions, DHA may facilitate DNA 
synthesis resulting in increases in histone protein levels, as observed in this study. Thus, 
DHA may contribute positively to minimizing the onset of neurodegenerative diseases, 
through maintaining the integrity of neuronal cell DNA synthesis and histone H3 and H4 
synthesis. Neurodegenerative diseases may involve the compromisation of the integrity 
of neuronal cells through inhibition of DNA synthesis with consequent termination of 
histone synthesis and subsequent apoptosis. Current research is underway to 
investigate the direct association of zinc with H3 and H4 and the affect of DHA on the 
post-translational modifications (PTMs) of histones. Understanding the molecular basis 
of the affect of zinc and DHA in neuroprotection may provide novel information on the 
treatment and management of neurodegenerative diseases.   
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CHAPTER 5 
ZINC AND DHA HAVE OPPOSING EFFECT ON THE EPIGENETIC REGULATION 
OF HUMAN NEURONAL CELLS 
 
PUBLICATION: 
Nadia Sadli, Leigh Ackland, Damitha De Mel, Andrew Sinclair, Cenk Suphioglu (2012) 
Effects of zinc and DHA on the epigenetic regulation of human neuronal cells,  
Cell Physiol Biochem. 29(1-2):87-98. 
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Summary 
 
Aim 
In this chapter, the aim was to investigate the effect of zinc and DHA on the post-
translational modifications (PTMs) of histone H3 in human neuronal cells.  
 
Methodology 
M17 human neuroblastoma cells were treated with and without zinc and DHA for 48 h. 
Immunoblotting and densitometric analysis of M17 cells were employed to determine 
changes in acetylation, deacetylation, methylation and phosphorylation of human 
histone H3 in response to zinc and DHA treatment. To investigate the potential 
occurrence of apoptosis in following zinc and DHA, anti-apoptotic Bcl-2 and pro-
apoptotic caspase-3 expression levels were also analyzed using Western immunoblot 
analysis. 
 
Results 
In response to pathophysiological levels of zinc, significant increases in deacetylation, 
methylation and phosphorylation of histone H3 and significant decreases in acetylation 
of histone H3 were observed, all pointing towards possible gene silencing and apoptosis. 
To further investigate the role of zinc in apoptosis, the levels of Bcl-2 and caspase-3 
were measured. Indeed, zinc reduced the levels of the anti-apoptotic marker Bcl-2 while 
increasing the apoptotic marker caspase-3 levels, correlating with cell viability assays.  
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Conversely, DHA treatment resulted in a significant increase in acetylation of histone H3 
and Bcl-2 levels and a significant decrease in deacetylation, methylation, 
phosphorylation of H3 and caspase-3 levels, suggesting that DHA promotes gene 
expression and neuroprotection. 
 
Conclusion 
In conclusion, these findings show the opposing effects of zinc and DHA on the 
epigenetic regulation of human neuronal cells and highlight the potential benefit of 
dietary intake of DHA for the control and management of neurodegenerative diseases. 
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5.1 INTRODUCTION 
It was shown in the previous chapter that histone H3 and H4 expression levels in human 
neuronal cells were down-regulated by zinc and up-regulated by DHA [152], suggesting 
a potential interaction between zinc and DHA in neurodegenerative diseases. As a 
building block of nuclesosome core particles carrying epigenetic information, histones 
are not only essential for packaging DNA into eukaryotic cells, but also affect the 
interactions between DNA and other chromatin associated proteins [158, 297]. Histones 
are among the most highly conserved proteins in eukaryotes [158], emphasizing their 
important role in the biology of the nucleus. Histones are involved in regulating gene 
transcription through the diverse post-translational modifications (PTMs) on their N-
terminal tails, which include acetylation, methylation, and phosphorylation [297].  
 
Since histone PTMs are closely related with gene transcription, neurodegenerative 
disorders such as Huntington disease [298, 299], Parkinson’s disease [300] and 
Alzheimer’s disease [301, 302] can result from aberrant epigenetic regulations. In this 
chapter, the effects of zinc and DHA on PTMs of histones, in particular histone H3, were 
identified in human neuronal cells.  
 
The potential occurance of neuronal apoptosis as a result of zinc toxicity was also 
investigated. Several apoptosis-regulatory genes are induced in apoptotic cells during 
neuronal injury and cellular toxicity [303].  Among these genes, caspase-3 [303] and Bcl-
2 [304, 305] are the most effective apoptotic regulators, as they play a decisive role in 
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the occurrence of apoptosis. Using Western blot analysis, the change in the expression 
levels of caspase-3 and Bcl-2 in M17 neuroblastoma cells were also measured in order 
to see whether DHA is able to inhibit zinc-induced apoptosis. 
 
The results suggest that zinc-induced alteration in histone PTMs may possibly contribute 
to cellular apoptosis, which is reduced by DHA, providing a potential mechanism that 
will establish the beneficial effect of DHA in neuroprotection.  
 
5.2 MATERIALS AND METHODS 
5.2.1 Treatment reagents and preparations 
Docosahexanoic acid (DHA, Sigma Aldrich, MO, USA), in final concentration of 10 µg/ml, 
was pre-incubated at 37°C in OptiMem media overnight to allow conjugation with 
media proteins. Anti-oxidant, Vitamin E (final concentration 0.05 µM/ml) was added to 
DHA treatment in order to stabilize DHA. Zinc (in the form of ZnCl2; 5 µM final 
concentration) was added to the cells on the day of experiment. To ensure that the 
differential histone PTMs were indeed zinc effect, as done in the previous chapter, the 
cell medium was first tested to have no zinc content. 
 
5.2.2 Experimental treatment of M17 neuroblastoma cells  
M17 neuroblastoma cell cultures were maintained and treated with and without zinc  
(5 µM final concentration) and DHA (10 µg/ml final concentration) for 48 h following 
procedures described in previous chapters. 
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5.2.3 Cell viability experiment 
Media was removed from cells cultured in 6-well plates, the cells washed with 
phosphate- buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 100 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4) to remove traces of previous serum growth medium. 0.3 ml of 0.025% 
trypsin/EDTA was added and cells were suspended in 0.5 ml Opti-MEM media, which 
was then mixed with 0.4% trypan blue solution (diluted 1:2). The number of trypan blue-
positive and negative-cells were counted on a haemocytometer using light microscope 
at 40x magnification.  
 
5.2.4 Protein extraction and quantitation 
Each sample was homogenized with 500 μl of lysis buffer (1% SDS, 10mM Tris HCl, pH 
6.8). Samples were then sonicated on ice at 7 watts for 15 sec, twice each using the 
Microson ultrasonic cell disruptor (Misonix, New York, USA) and centrifuged at 14,000 x 
g for 5 min. Cell debris was then discarded and sample aliquots stored at -80°C until 
required. Quantification of the protein samples was performed using BCA protein assay 
kit (Perbio, Rockford, USA), following manufacturer’s instructions. Optical density values 
for known bovine serum albumin (BSA) standards as well as 1:3 and 1:5 dilutions of 
lystate samples were recorded on the Beckman DU 530 Life Science UV/Vis 
spectrophotometer at 595nm using Genesis Lite 3.03 computer software. Protein 
concentrations were obtained from standard curve of absorbance vs. protein 
concentration (μg/ml), using standards of known concentrations. 
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5.2.5 One-dimensional electrophoresis and Western immunoblot analysis 
 
The level of each post-translational modification of histones in response to zinc and DHA 
treatment were analyzed using Western blot analysis.  Protein concentration of 25 µg 
with total volume of 20 µl per well were run on 15% SDS–PAGE and transferred onto 
nitrocellulose membrane (Whatman, Dassel, Germany). After blocking with 1% (w/v) 
non-fat skim milk in 1 x TBS for 1 h at room temperature, membranes were incubated 
overnight at 4°C with monoclonal primary antibody with the dilution of 1:1,000 for anti-
acetyl-H3 lys9; anti-HDAC1, 2, 3; anti-di-methyl-H3 lys4, lys9, lys27, lys36, lys79; and 
anti-phospho-H3 thr3 (Cell Signaling Technology, Inc., MA). After washing with TBS 
solution three times for 5 min each, membranes were incubated with 1:2,000 dilution of 
goat anti-rabbit IgG horseradish-peroxidase (HRP) conjugated secondary antibody (Cell 
Signaling Technology Inc., MA) for 1 h at room temperature. Membranes were 
visualized using Immobilan Western Chemiluminesence HRP substrate (Millipore 
Corporation, CA, USA), according to manufacturer’s instructions. 
 
Developed membranes were stripped for 15 min at RT using 1 ml of Re-blot Plus-strong 
(Chemicon International, CA, USA), diluted 1:10 in MilliQ water, and re-probed for 
histone H3 using anti-histone-H3 monoclonal primary antibody (1:1,000 dilution) 
followed by goat anti-rabbit IgG HRP conjugated secondary antibody (1:2,000 dilution, 
Cell Signaling Technology Inc). In order to ensure equal protein loading in all wells, the 
membranes were re-probed for β-actin using mouse anti-β-actin (Sigma Aldrich, USA) 
primary antibody (1:4,000 dilution) followed by anti-mouse HRP antibody (1:4,000 
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dilution, Chemicon International) and developed as described above. To ensure specific 
antibody binding, negative control western blots (probed with detection/secondary 
antibodies only) were performed showing no binding (data not shown). 
 
5.2.6 Apoptosis assay                                                                                                                                                 
Protein lysates (25 µg concentration with 20 µl total volume per well) were subjected to 
15% (w/v) SDS-PAGE and transferred onto nitrocellulose membrane (Whatman), as 
described previously. The membranes were probed for apoptosis markers; mouse 
monoclonal Bcl-2 (Abcam, Cambridge, UK) and rabbit polyclonal antibody for active 
caspase-3 (Chemicon International). Both antibodies were prepared in 1:100 dilutions 
with 1 x TBS, and membranes were blocked with 1% casein blocking-buffer prior to 
incubation with Bcl-2. No blocking was required for caspase-3. Antibodies were 
incubated with rabbit and mouse secondary antibodies (1:1,000 for Bcl-2, 1:10,000 for 
caspase-3) and developed as described previously. All membranes were photographed 
using Fujifilm LAS-300, and the subsequent densitometry analysis of bands was done 
with the Fujifilm Multi Gauge V3.0 program (Fujifilm, Tokyo, Japan). 
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5.2.7 Statistical analysis 
The data were analyzed using the Statistical Package for Social Sciences (SPSS) 
programme, release 16.0 for Windows (SPSS, Chicago, IL, USA). The results were 
analyzed by student’s t-test to determine any statistically significant difference in signal 
intensity between zinc alone and DHA treatments. The statistical significance was set at 
*p < 0.05. 
 
5.3 RESULTS 
In the previous chapter, it was observed that zinc and DHA affect expression levels of 
histone H3 and H4 [152]. Here the aim was to investigate the effects of zinc and DHA on 
the post-translational modifications (PTMs) of histone H3. Histone H3 has the longest N-
terminal tail among all core histones (Fig. 5.1), and where most modification sites are 
found [306].  
 
 
 
Figure 5.1:  Post-translational modification positions of histone H3 in human neuronal 
cell analyzed in this study. Ac= acetylation; Me= methylation; P=phosphorylation. 
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5.3.1 Effect of zinc and DHA on acetylation of histone H3 (K9) 
 
In order to investigate the effect of zinc and DHA on the acetylation of histone H3 (K9), 
M17 human neuronal cells were grown in culture medium in the presence and absence 
of zinc and DHA. In the presence of zinc and the absence of DHA (zinc effect), acetylated 
histone H3 (K9) levels were significantly decreased (Fig. 5.2). On the other hand, DHA in 
the presence of zinc, significantly increased histone H3 (K9) acetylation levels back to 
the control levels (without zinc and DHA) (Fig. 5.2). 
 
Figure 5.2: Effect of zinc and DHA on acetylation of histone H3 (K9) in M17 human 
neuronal cells. Densitometric analysis, in arbitrary units (AU), of a Western blot (with 
corresponding protein bands shown at the bottom) to quantitate acetylation of histone 
H3 (K9) in M17 cells following treatment with (+) and without (-) zinc (final 
concentration of 5 μM) and with (+) or without (-) 10 μg/ml DHA. Densitometric analysis 
show the values obtained from acetylated histone H3 (K9), compared with total H3 and 
normalized with β-actin expression level. The data are shown as means (n=3, *P<0.05).  
 
 
 
 
115 
 
5.3.2 Effect of zinc and DHA on histone deacetylase (HDAC) 1, 2, 3 
Western blot analysis was performed to investigate the changes in expression levels of 
histone deacetylase (HDAC) 1, 2, and 3, using highly specific anti-HDAC 1, 2 and 3 
antibodies. Zinc caused significant up-regulation of HDAC1, 2 and 3 compared with the 
control (without zinc and DHA) (Figs. 5.3A- 5.3C), while DHA caused significant down-
regulation of HDAC1, 2 and 3 (Figs. 5.3A-5.3C, respectively), as measured by 
densitometric analysis. 
 
A. 
 
 
 
 
 
 
 
 
 
* 
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B. 
 
C. 
 
 
Figure 5.3: Effect of zinc and DHA on histone deacetylases (HDACs) expression levels in 
M17 human neuronal cells. Densitometric analysis, in arbitrary units (AU), of a Western 
blot (with corresponding protein bands shown at the bottom, for HDAC1) to quantitate 
the expression levels of HDAC1 (A), HDAC2 (B), and HDAC3 (C), following zinc (5 μM) and 
DHA (10 μg/ml) treatments. The results are shown as means (n=3, *P<0.05). The given 
values are the ratios of the density of HDAC1, 2 and 3 and the corresponding β-actin 
bands. 
 
 
5.3.3 Effect of zinc and DHA on di-methylation of histone H3 (K4), (K9), (K27), (K36), 
(K79) 
In order to assess the effect of zinc and DHA on dimethylation of histone H3 (K4), (K9), 
(K27), (K36), (K79), Western blot analysis was performed using human neuronal cells 
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that were grown in the presence and absence of zinc and DHA, as described previously. 
Concurrent analysis of di-methylation levels of histone H3 revealed that di-methylated 
H3 (K4) and (K27) are significantly increased upon zinc treatment and significantly 
decreased with the addition of DHA (Figs. 5.4A and 5.4C). Di-methylated H3 (K79) also 
showed a significant increase with zinc treatment, but an even more significant increase 
was observed with DHA treatment (Fig. 5.4E). In contrast, zinc significantly decreased 
the expression levels of di-methylation of histone H3 (K9) and (K36), while DHA caused a 
significant increase (Figs. 5.4B and 5.4D). These results demonstrated the different roles 
of methylation of histone H3 at distinct amino acids residues, which provides a variety 
of interpretation in regulating neuronal cell gene expression.  
 
A.  
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B. 
 
 
C. 
 
D. 
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E. 
 
Figure 5.4.  Effect of zinc and DHA on di-methylation of histone H3 in M17 human 
neuronal cells. Quantitative analysis of dimethylation levels of histone-H3 (K4) (A), (K9) 
(B), (K27) (C), (K36) (D) and (K79) (E) by densitometric analysis, expressed in arbitrary 
units (AU), of a Western blot (with corresponding protein bands shown at the bottom, 
for Lys4), following treatment with or without zinc (5 μM) and DHA (10 μg/ml). 
Densitometric analysis show the values obtained from di-methylation of histone H3, 
compared with total H3 and normalized with β-actin expression level. The results are 
shown as means (n=3, *P<0.05). 
 
 
 
5.3.4 Effect of zinc and DHA on phosphorylation of histone H3 (T3)  
The effect of zinc and DHA on Histone H3 phosphorylation at Threonine 3, -11, and 
Serine 10, -28 were also investigated. However, only H3 (T3) phosphorylation was seen 
in M17 cells. The results showed that phosphorylation of H3 (T3) was significantly 
increased upon zinc treatment and significantly decreased with DHA (Fig. 5.5). 
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Figure 5.5: Effect of zinc and DHA on phosphorylation of histone H3 (T3) in M17 
human neuronal cells. Densitometric analysis, in arbitrary units (AU), of a Western blot 
(with corresponding protein bands shown at the bottom) used to quantitate 
phosphorylation of histone H3 (T3), compared with total H3 and normalized with β-actin 
expression level, following treatment with or without zinc (5 μM) and DHA (10 μg/mL). 
The results are shown as means (n=3, *P<0.05).  
 
 
 
5.3.5 Western blot analysis of caspase-3 and Bcl-2 activation in M17 neuroblastoma 
cells in response to zinc and DHA 
The aim for this study was to determine whether anti-apoptotic Bcl-2 and pro-apoptotic 
caspase- 3 are involved in the cellular pathway affected by zinc and DHA in M17 cells, by 
investigating their expression levels using Western blot analysis (Figs. 5.6A and 5.6B). 
The results showed that both zinc and DHA opposingly modulate the levels of Bcl-2 and 
caspase-3 in M17 cells. Increase in zinc levels caused significant up-regulation of 
caspase-3 and down-regulation of Bcl-2 expression, while DHA treatment of M17 cells 
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significantly increased expression levels of Bcl-2 and significantly reduced caspase-3 
levels (Figs. 5.6A and 5.6B). 
 
A. 
 
B. 
 
Figure 5.6: Effect of zinc and DHA on Bcl-2 and caspase-3 expression levels in M17 
neuroblastoma cells. Densitometric analysis, in arbitrary units (AU), of a Western blot 
(with corresponding protein bands shown at the bottom, for caspase-3) to quantitate 
anti-apoptotic marker, Bcl-2 (A) and apoptotic marker, caspase-3 (B) expression levels in 
M17 cells following treatment with (+) and without (-) zinc (final concentration of 5 μM) 
and with (+) or without (-) 10 μg/ml DHA, when compared with β-actin loading control. 
The data are shown as means (n=3, *P<0.05).  
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5.4.6 DHA protects neuronal cells against zinc-induced cellular apoptosis 
Cell viability assay using trypan blue exclusion was conducted in order to confirm the 
Bcl-2 and caspase-3 expressions results (Fig. 5.7). Indeed, there was a direct correlation 
with the Bcl-2 and caspase-3 results, in which zinc treatment reduced and DHA 
treatment increased M17 cell viability. 
 
 
Figure 5.7: Viability of M17 cells in response to zinc in the presence and absence of 
DHA after 48 h. Cell viability was determined by the trypan blue exclusion assay. The 
results were expressed as mean ± SD of three independent experiments. Student’s t-test 
was used for statistical evaluation between treatment of DHA with and without zinc and 
a P value of <0.05 was considered significant. (*) = significant. 
 
5.4 DISCUSSION 
5.4.1 The effect of zinc and DHA on acetylation of histone H3 (K9)  
The results showed that zinc decreased acetylation of H3 (K9), suggesting the potential 
involvement of zinc in neurodegenerative disease through alteration of acetylation 
homeostasis in neuronal cells. During acetylation dyshomeostasis, transcriptional 
regulation may be affected and this has been implicated as the prime cause of several 
neurodegenerative diseases [215, 299]. The altered gene transcription may cause 
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opposite effects from normal gene regulation pattern, which is attributed to 
degenerative fate of neurons that subsequently reduce the expression of survival-
associated genes by altered acetylation and, at the same time, stimulate the expression 
of death-inducing genes [215].       
 
On the other hand, DHA increased H3 (K9) acetylation, indicating the ability of DHA to 
normalize the histone H3 (K9) acetylation to the basal level (control) and abolish the 
effect of zinc. Although the molecular basis underlying the neuroprotective effects of 
DHA in epigenetic regulation remains unknown, these results may suggest the 
contribution of DHA in neuroprotection through reinstating the altered acetylation 
homeostasis, which would possibly induce the expression of potentially neuroprotective 
genes. Indeed, it has been shown here that DHA contributes to anti-apoptotic, Bcl-2 up-
regulation, thereby reducing neuronal cell death. 
 
5.4.2 Effect of zinc and DHA on histone deacetylases (HDACs) 1, 2, 3 expression 
levels 
HDAC enzyme activity has been shown to increase in dying neurons due to loss of 
counterbalancing effects of HAT activity [215]. The results suggest that the increase of 
zinc can also contribute to the neurodegenerative process through up-regulating HDAC 
enzyme expression levels, and therefore affecting histone deacetylation (Fig. 5.3).  
The HDAC catalytic domain contains a Zn2+ ion, in the active site, which contributes 
significantly to its catalytic activity [236, 307]. X-ray crystallographic studies have shown 
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that HDAC inhibitors can chelate zinc ions in the catalytic sites of HDACs and therefore 
block substrate access to the active zinc ions and inhibit the deacetylation reaction [236, 
308]. 
 
It has been established that the isotypic selective inhibition of HDAC enzymes may be a 
potential treatment for neurodegenerative diseases. So far, the HDAC inhibitors 
investigated in treating neurodegenerative diseases are very limited and mainly focused 
on the well-established experimental drug trichostatin A (member of hydroxamic acid 
group) and the clinically used HDAC inhibitors sodium butyrate, valproic acid, 
phenylbutyrate and vorinostat, which belong to short chain fatty acid group that are 
known to be able to penetrate the blood-brain barrier [309]. Since DHA crosses the 
blood-brain barrier [310], these data suggests that it may possibly have neuroprotective 
characteristics that mimic the behavior of HDACs inhibitors.  
 
Generally, increase in HDACs during neurodegenerative disease are associated with an 
increase in gene repression and transcriptional dysfunction of certain transcription 
factors (TFs) such as CREB, which is important in regulating the expression of pro-
survival elements such as Bcl-2 [215, 311]. This chapter demonstrated how zinc 
contributed to dysfunctional acetylation homeostasis in M17 cells by up-regulating 
HDACs, which influence the reduction of HATs and consequently histone acetylation 
levels. DHA, however was shown to re-establish the imbalance of acetylation 
homeostasis and therefore capable of correcting the down-regulation of specific genes 
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caused by reduction in histone acetylation. The mechanism by which DHA inhibits HDAC 
expression is unclear; perhaps DHA directly chelates zinc from catalytic sites of HDACs or 
hinders zinc binding to the enzymes. Indeed, it has been recently reported that DHA and 
zinc chelator act synergistically to kill tumor cells [312]. 
 
5.4.3 Effect of zinc and DHA on di-methylation of histone H3 (K4), (K9), (K27), (K36), 
(K79)  
The results suggest that the increase in H3 (K4) di-methylation following zinc treatment 
is likely to be due to overexpression in histone methyltransferase, SET9/7, which may 
result in ‘hyperstabilization’ and activation of nuclear p53 which then lead to the 
induction of cell-cycle arrest and apoptosis [186], a key feature in the pathology of 
neurodegenerative disorders, such as AD. On the other hand, DHA treatment of M17 
cells significantly decreased H3 (K4) di-methylation, which possibly relates to the 
decrease in p53 protein activity, and subsequent inhibition of apoptosis. The molecular 
mechanism of zinc in regulating p53 activity by overexpressing the SET7/9 
methyltransferases is unclear. However, the results of this study suggest that zinc may 
contribute to the regulation of cell apoptosis through increasing H3 (K4) methylation. 
Several developmental disorders with abnormalities in the nervous system have been 
linked to abnormalities in DNA methylation, such as Down’s syndrome, which is 
characterized by chromosome abnormality and associated with mental retardation 
[313]. Based on our results, it is possible that zinc may be involved in neurodegenerative 
process through inhibition of H3 (K9) di-methylation, which is associated with reduction 
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in DNA methylation [153, 314]. This will consequently enhance DNA strand breakage 
that can also impair DNA repair system, resulting in genetic mutation and chromosome 
abnormality or possibly triggering apoptosis [153, 315].  DHA, on the other hand 
increased H3 (K9) di-methylation to basal level (control), indicating its neuroprotective 
ability to re-establish the effect of H3 (K9) hypomethylation caused by zinc treatment, 
which may in return normalize the DNA hypomethylation and therefore reduce genomic 
instability and chromosome structures, leading to a reduction/prevention of 
neurodegenerative diseases.  
 
Di-methylation of histone H3 (K27) is generally associated with gene silencing [316-318]. 
A recent study has reported the importance of H3(K27) di-methylation in cellular 
growth, where repression of H3(K27) methylation caused significant effect on cell cycle 
progression through G1 arrest, which led to cell growth inhibition and eventually 
apoptosis [319]. Based on Western blot analysis, zinc caused a significant increase in H3 
(K27) di-methylation compared with the control (without zinc and DHA), while DHA 
caused a significant decrease in H3 (K27) di-methylation, restoring the basal level. So far, 
the link between H3 (K27) di-methylation and neurodegenerative diseases is still 
unclear. However although not investigated here, it is possible that the increase in 
H3(K27) di-methylation caused by zinc leads to the gene repression as well as cell 
growth inhibition which resulted in cell death.  Therefore, DHA can be proposed to 
reduce gene silencing by decreasing di-methylation of H3 (K27), which in turn induces 
cell cycle progression, cell growth and reduction in apoptosis. 
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The role of H3 (K36) di-methylation is associated with the euchromatin region [320] at 
the individual gene level that leads to gene activation [320, 321]. H3 (K36) di-
methylation has been shown by various studies to play a role in mRNA synthesis in 
eukaryotic organisms through transcription elongation process as well as its interaction 
with RNA polymerase II [322]. Reduction of H3 K36) di-methylation decreases RNA 
polymerase II phosphorylation which then leads to transcription elongation defect [323, 
324]. The results obtained in this study showed a decrease in H3 (K36) di-methylation by 
zinc treatment and increase by DHA. The contribution of transcription elongation defect 
in the process of neurodegenerative disorders is still unclear. However, it is possible that 
zinc may contribute to neurodegenerative process through mediating changes in H3 
(K36) di-methylation, which is functionally linked with mRNA synthesis and therefore 
regulation of gene expression. Western blot analysis also confirmed the reverse effect of 
DHA, which resulted in increase of H3 (K36) di-methylation in M17 cells. DHA, however, 
may have normalized the effect of zinc by phosphorylating RNA polymerase II and 
therefore increasing transcription elongation through increasing di-methylation of H3 
(K36). 
 
It has also been recently shown that H3 (79) methylation is associated with DNA repair 
system [184, 325]. The rate of DNA repair is dependent on several factors such as the 
extracellular environment, cell types and how severe the damage is. Cells that have 
accumulated large amounts of damage can possibly lead to cell death or apoptosis. H3 
(K79) methylation is required for the recruitment of the DNA-repair-protein p53 binding 
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protein (53BP1) that is shown to be a sensor of DNA double strand breaks (DSBs), which 
in turn activate ataxia telangiectasia-mutated protein (ATM) ( a DNA damage signaling 
kinase which then also mediates the activation of p53 (tumour suppressor)) through 
chk2 (checkpoint gene) and subsequently lead to cell cycle arrest or apoptosis [326, 
327]. It was observed that zinc increases H3 (K79) di-methylation in neuronal cells while 
DHA causes further increase in H3 (79) di-methylation. The enhanced increase of di-
methylation of H3 (K79) by DHA may suggest different outcomes. Indeed, zinc-induced 
neuronal death is associated by DNA DSBs [328], which is somehow mediated by H3 
(K79) methylation. The significant increase in H3 (K79) methylation by DHA treatment 
may indicate its neuroprotective effect by inducing DNA repair system. It has been 
reported that dietary omega-3 polyunsaturated fatty acids (PUFAs) are effective in 
attenuating oxidative stress-induced apoptosis and protecting the cells from DNA 
damage caused by ultraviolet radiation-induced p53 expression [329]. A reduction in 
p53 expression following dietary PUFAs is also anticipated to reflect the presence of less 
DNA damage and therefore allowing cell survival [329]. From this study, further increase 
in di-methylation of H3 (K79) in response to DHA would may be involved in reducing p53 
expression levels and therefore inhibit cell apoptosis (Fig. 5.4E). 
 
5.4.4 Effect of zinc and DHA on phosphorylation of histone H3 (T3)  
Phosphorylation is involved in ‘methyl-phos’ mechanism, which is a concept that local 
phosphorylation could regulate binding of an effector protein of adjacent methylation 
sites [330], where neighbouring modifications act together as ‘binary switches’. The 
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phosphorylation of Thr3 regulates the binding of chromodomain protein Chd1 to 
dimethyl H3 (K4), which has been associated with an “on” or “off” transcriptional state. 
Binding of Chd1 to methylated H3 (K4) destabilizes the nucleosome and expose DNA for 
gene expression, which is antagonized in vitro by phosphorylation of neighbouring 
threonine 3 (Thr3) [331]. This binding dissociation reduces the interaction with 
transcriptional elongation factors and therefore reduces gene transcription and 
subsequently induces apoptosis [331]. The results show how phosphorylation of H3 (T3) 
is significantly increased upon zinc treatment and decreased with DHA. Increase in zinc 
levels may be involved in reducing gene transcription and increasing apoptosis through 
H3 (T3) phosphorylation, which in turn dissociate the binding complex between H3 (K4) 
methyl group and its effector protein.  However, DHA treatment reduced the 
phosphorylation H3 (T3), which may increase Chd1 protein binding to dimethylated H3 
(K4) and may therefore increase recruitment of transcription elongation, gene 
transcription and subsequent reduction in apoptosis, although this needs to be fully 
tested in future studies.  
 
5.4.5 DHA inhibit cellular apoptosis through restoring zinc- induced alteration in 
caspase-3 and Bcl-2 expression levels in M17 cells 
The observation that zinc increased caspase-3 and reduced Bcl-2 levels, suggests the 
potential occurrence of apoptosis of zinc-treated M17 cells, which is representative of 
neurodegenerative conditions such as AD, where intracellular zinc is elevated while DHA 
level is reduced. Conversely, DHA treatment of M17 cells increased expression levels of 
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Bcl-2 and reduced caspase-3, suggesting that DHA may exclusively activate the 
extracellular signal regulated kinase/ mitogen-activated protein kinase (ERK/MPK) 
pathway to promote cell survival, which lead to the up-regulation of Bcl-2 and inhibition 
of caspase-3 activation [332]. The study by Akbar et al (2006) also showed the 
involvement of DHA in neuronal cell survival by driving Akt translocation, which results 
in activation of Bcl-2 and subsequent suppression of caspase-3 activity, leading to 
inhibition of apoptosis in neuronal cells [145]. The findings with Bcl-2 and caspase-3 
highlight the importance of DHA in neuroprotection and zinc in apoptosis. 
 
5.4.6 DHA protects neuronal cells against zinc-induced cellular apoptosis. 
The viability of M17 cells in the zinc and DHA- treated groups and their corresponding 
controls were expressed as percentage (%) change. Approximately 34% decrease in M17 
cell viability was observed following zinc treatment for 48 h.  DHA has shown to inhibit 
zinc-induced toxicity by restoring cell viability. These findings are supported by previous 
findings in this chapter which indicate the neuroprotective effect of DHA in restoring 
zinc-induced alteration in epigenetics and subsequent cell death.  
 
Zinc toxicity has been reported to affect gene transcription, which is proposed to be 
mediated by alteration in the epigenetic patterns. Anti-apoptotic and pro-apoptotic 
markers were assessed in this study to look at the potential occurrence of cellular 
apoptosis, which is also believed to be mediated by a change in the epigenetic pattern. 
Any other functions of the epigenetic changes, and their influence in the regulation of 
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specific genes following zinc and DHA treatment, were not tested as it was beyond the 
scope of this study. Here, the aim was to see whether or not DHA could restore zinc-
induced alteration of histone PTMs and to confirm that zinc and DHA indeed have direct 
interrelationships, mediated by histones and histone PTMs. Indeed, how the epigenetic 
changes link to their functions will be investigated in future studies. 
 
5.5 CONCLUSION 
The key findings and their potential relevance in neurodegenerative diseases (e.g. zinc) 
or neuroprotection (e.g. DHA), as supported by current literature, are summarized in 
Figures 5.8 and 5.9. The data show that zinc reduced histone acetylation and increased 
HDACs, which represent a critical step in the apoptotic process, while DHA reinstated 
the imbalance of acetylation homeostasis, indicating its potential neuroprotective ability 
to ameliorate neurodegenerative diseases. Histone methylation and phosphorylation 
were also significantly altered as a result of zinc and DHA treatment, and therefore 
proposed that these two essential nutrients may contribute to the epigenetic regulation 
of neuronal cell gene expression. However, it seems that zinc metabolism may 
somehow be dependent on DHA metabolism and vice-versa, and that DHA may 
normalize the effect of increased zinc levels in epigenetic alteration and therefore 
increase neuroprotection. It was observed that zinc and DHA have distinct epigenetic 
patterns; this suggests they may have opposing effects in the progression of 
neurodegenerative diseases. Such novel findings highlight the potential importance of 
dietary intake of DHA for the management and treatment of neurodegenerative 
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diseases. In future studies, it will be of interest to test how these epigenetic changes 
regulate the expression of anti-apoptotic or proapoptotic genes (e.g. p53). In addition, it 
will be important to assess the epigenetic effects observed in this study in other 
neuronal cells and in appropriate animal models. 
 
Figure 5.8: Schematic representation of “zinc effect” on histone post-translational 
modifications. The schematic diagram shows the effect of zinc on histone H3 post-
translational modifications and the potential downstream effects leading to 
neurodegenerative diseases, as supported by current literature.  The findings of this 
chapter are shown by the shaded boxes. HDAC= histone deacetylase; CREB= cAMP 
response element-binding; Bcl-2= B-cell lymphoma 2; DSBs= double strain breaks; ATM= 
ataxia telangiectasia mutated, Chk2= checkpoint kinase 2; Chd1= chromodomain-
helicase-DNA-binding 1. 
 
 
Figure 5.9: Schematic representation of “DHA effect” on histone post-translational 
modifications. The schematic diagram shows the neuroprotective effect of DHA by 
histone H3 post-translational modifications and the potential downstream effects 
leading to reduction in neurodegenerative diseases, as supported by current literature. 
The findings of this chapter are shown by the shaded boxes. HDAC= histone deacetylase; 
CREB= cAMP response element-binding; Bcl-2= B-cell lymphoma 2; Chd1= 
chromodomain-helicase-DNA-binding 1; RNA pol= Ribonucleic acid polymerase. 
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CHAPTER 6 
 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
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6.1  INTRODUCTION 
This thesis covers several aspects of zinc and polyunsaturated fatty acid DHA 
interactions in human neuronal cells, which focus on the neuroprotective effects of 
DHA in restoring zinc-mediated alteration in cellular bioenergetic functions, 
epigenetic patterns and gene expressions. The potential pathways of zinc toxicity in 
human neuronal cells are extracted into a summary to which our findings are related. 
This discussion will also include the potential therapeutic intervention of zinc-induced 
neuronal injury with DHA and a look into possible future directions for zinc and DHA 
molecular interactions. 
 
This chapter provides a general discussion of the thesis, describing the findings and 
possible links between each result chapter in relation to:  
1. Identifying the potential mechanism and effect of mitochondrial zinc toxicity 
as well as the neuroprotective effect of DHA in restoring cellular bioenergetic 
dysfunction following zinc treatment; 
2. Determining whether DHA and CoQ10 have independent or additive effects 
against Aβ- and zinc-induced defects in energy metabolism and mitochondrial 
respiratory function in M17 neuroblastoma cells; 
3. Using proteomic analysis to identify the differentially expressed proteins in 
response to zinc and DHA treatment in human neuronal cells; 
4. The involvement of zinc and DHA in the epigenetic modification of histones, 
which therefore affecting gene expressions in human neuronal cells. 
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To elucidate the possible mechanisms in which DHA restores and inhibits zinc-
induced cellular dysfunction, the signaling pathway involved in zinc toxicity will be 
investigated first. This could provide the insight into apoptosis of human neuronal 
cells and neurodegenerative conditions induced by altered zinc homeostasis and the 
potential therapeutic mechanisms of DHA.  
 
6.2 MITOCHONDRIAL DYSFUNCTION MAY BE THE EARLY EVENT OF ZINC-
INDUCED TOXICITY IN HUMAN NEURONAL CELLS  
Perhaps the best understanding of the role of altered zinc homeostasis (caused by 
excess zinc efflux) in mitochondrial dysfunction comes from the study of zinc toxicity 
in altering bioenergetic functions, which lead to the reduction in ∆ψm, along with the 
capacity to synthesize ATP production (Chapters 2 and 3). Uncoupled respiration and 
maximal respiratory capacity are also decreased (Chapter 3) following zinc, indicating 
that this Ca2+-dependent process produces a major functional defect in the electron 
transport chain [333]. 
 
The disruption of mitochondrial function eventually leads to a cell death cascade 
involving the release of pro-apoptotic molecules and ROS [334]. This is consistent 
with the results showing that hydrogen peroxide, H2O2 were significantly increased 
following zinc treatment in M17 neuroblastoma cells, which suggest the potential 
occurance of neuronal cell death as a consequence of elevated zinc ions (Chapter 3). 
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Zinc is thought to cause neuronal cell injury by targeting mitochondria and cellular 
energy metabolism. While it is obvious that zinc can disrupt mitochondrial function, it 
is unclear whether zinc acts externally or if mitochondria import zinc into the matrix.  
Given that mitochondria are semiautonomous organelles that are capable of 
transcription and translation and therefore require zinc in such process.  It is possible 
that the mitochondrial membrane possess transporters responsible for regulating 
zinc uptake. Studies suggested that zinc may enter mitochondria and produce 
immediate effect within 24 h incubation (Chapter 3), perhaps mediated by 
mitochondrial calcium uniporter [280, 335].  
 
Zinc may enter mitochondrial matrix where they start to interact with endogenous 
target molecules, causing mitochondrial dysfunction. The biochemical changes 
induced by zinc toxicity, such as ROS generation, depletion of ATP as well as a 
decrease in ∆ψm (Chapter 3) may possibly be considered as causative factors for an 
abrupt increase in the mitochondrial inner membrane permeability, which is believed 
to be due to the opening of mitochondrial membrane transtition pores [241, 244]. 
This then causes an alteration in proton influx into mitochondrial matrix, which leads 
to a rapid dissipation of membrane potential and reduction in ATP turnover rate, as 
observed in my study (Chapter 3). This condition has been reported to be associated 
with mitochondrial swelling and release of protein from intermembrane space such 
as cytochrome c. This in the end may cause a complete failure of maintenance of 
neuronal cell function and possibly culminating in cell death.  
139 
 
The possible zinc-induced neurotoxic mechanism in mitochondrial function is shown 
in Figure 6.1. It is important to note that although the model presented here is 
broadly accepted by current literature, the function of membrane transition pores, 
and the release of apoptosis-mediated proteins such as cytochrome c were not 
experimentally tested in this thesis. Therefore, this potential mechanism induced by 
zinc is still hypothetical. 
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Figure 6.1: Possible neurotoxic mechanisms induced by zinc toxicity in 
mitochondria. Cellular injury and neurodegenerative disease such as AD are 
characterized by cellular dysfunction, which mitochondrial destruction is the early 
event.  Increase in [Zn2+]i is associated with an increase transport of Zn
2+ into 
mitochondria, which is possibly mediated by mitochondrial uniporter.  Zn2+ can 
inhibit both β-oxidation and the respiratory chain, leading to a decrease in 
mitochondrial and cellular ATP levels. Additionally, the uncoupled oxidative 
phosphorylation in combination with the inhibition of the electron transport, 
increases the generation of reactive oxygen species (ROS) leading to permeabilization 
of the mitochondrial membranes by opening of the mitochondrial permeability 
transition pore, which is located in the inner and outer mitochondrial membrane. The 
osmotically driven influx of water results in an increase in mitochondrial volume and 
a rupture of the outer mitochondrial membrane. Proteins from the intermembrane 
space (i.e. cyt c) can be released into the cytoplasm and activate apoptotic pathways. 
Cyt c = cytochrome c; AIF = apoptosis-inducing factor; ∆Ψm = membrane potential; 
ATP = adenosine triphosphate. 
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6.3 ZINC-MEDIATED MITOCHONDRIAL DYSFUNCTION MAY LEAD TO AN 
ALTERED GENE REGULATION 
As previously mentioned, mitochondria are the major producers of ROS in the cells, 
which are generated as by-products of aerobic respiration and various other 
catabolic and anabolic processes [336]. Hydrogen peroxide (H2O2), which is converted 
from superoxide anion (O2
-), is increased following pathophysiological levels of zinc in 
M17 cells (Chapter 3). Once produced, ROS react with proteins and nucleic acids 
causing oxidative damage to these macromolecules [337, 338]. It has been reported 
that ROS readily attack DNA and generate a variety of DNA lesions, such as oxidized 
DNA bases and DNA strand breaks, which ultimately lead to genomic instability [339]. 
 
In Chapter 4, proteomic analysis showed that histones were the key differentially 
expressed proteins in response to zinc and DHA interaction. Zinc treatment 
decreased histones protein and mRNA levels in M17, which may be associated with 
the reduction in DNA synthesis (Chapter 4). These data may suggest a link between 
zinc-induced mitochondrial dysfunction and accumulation of ROS, which have the 
tendency to disrupt DNA synthesis and therefore inhibit histone transcription. 
Insufficient ATP synthesis due to zinc-induced bioenergetic dysnfunction (Chapters 2 
and 3) may also account for the inhibiton in DNA and histone synthesis in M17 cells 
(Chapter 4).  
 
142 
 
Disturbance of mitochondrial function following zinc supplementation in M17 cells 
has the potential to affect nuclear DNA, which can in turn affect the genomic 
function. This hypothesis is supported by a study that showed a link between 
aberrant production of ATP from oxidative phosphorylation and inhibition in nuclear 
DNA synthesis in mammalian cells [340]. This is also consistent with the data in 
Chapter 4 on the reduction of histone expression levels following zinc treatment, in 
which their synthesis may be associated with inhibition of DNA synthesis (Chapter 4). 
The results suggest that not only does ROS accumulation in the cells lead to a 
significant reduction in histone mRNA and protein levels, but zinc-mediated ATP 
depletion may also affect histones and DNA synthesis and may therefore affect gene 
transcription.  
 
6.4 ZINC-MEDIATED MITOCHONDRIAL DYSFUNCTION MAY BE ASSOCIATED 
WITH ALTERED EPIGENETIC PATTERNS  
Chapter 5 showed that zinc supplementation in M17 cells reduced acetylation, which 
is associated with increased gene transcription [341, 342] and increased histone 
deacetylases (HDACs) enzyme, which confers repressed gene transcription 
(deacetylation) [343].  ROS accumulation as a result of mitochondrial dysfunction has 
been shown to regulate both genetic and epigenetic cascades underlying altered 
gene expression in disease condition [98]. ROS-related H2O2 causes epigenetic 
alteration such as DNA damage methylation, which is mediated by accumulative 
change in chromatin structure.  This epigenetic perpective on the free radical theory 
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of development was supported by Hitchler and Domann [344] through oxidation of 
DNA and histone methyltransferases (HMT).  
 
The activity of enzymes and co-factors involved in epigenetic control, such as HDACs 
and HMTs, are linked to glycolysis and oxidative phosphorylation [344]. Redox status 
may also influence the function of epigenetic enzymes and the proteins that bind to 
their products [344]. From this, it is apparent that the epigenome relies heavily upon 
mitochondrial function. 
 
A schematic diagram on how each of the epigenetic alteration regulate gene 
expression that lead to cellular apoptosis and neurodegenerative condition is shown 
in Figure 5.8 (Chapter 5). This discussion chapter also sought to expand upon current 
literature regarding the zinc-induced metabolic defects and epigenetic alteration (Fig. 
6.2). 
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Figure 6.2: Schematic model representing the effect on zinc-induced mitochondrial 
dysfunction and alteration in epigenetic function. ROS accumulation in cells leads to 
epigenetic alteration, which may induce mutation and alteration in gene 
transcription that subsequently lead to cell death or neurodegenerative conditions. 
Insufficient ATP production, which is required for epigenetic enzyme synthesis, may 
also result in epigenetic dyshomeostasis. Inhibition in oxydative phosphorylation may 
affect enzyme and co-factor metabolism, leading to reduction in enzyme activity and 
consequently alteration in the epigenetic control. Zn2+= zinc ions, ROS= reactive 
oxygen species, ATP= adenosine triphosphate, OXPHOS= oxidative phosphorylation. 
 
 
6.5 MECHANISM OF NEUROPROTECTIVE DHA AGAINST ZINC TOXICITY 
For every results chapter presented in this thesis, the neuroprotective effects of DHA 
against zinc toxicity were examined. High levels of oxidative stress, disruption of the 
electron transport chain and reduction in gene regulation are sufficient to cause 
apoptosis of neuronal cells. It was observed that DHA has the ability to restore zinc-
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induced cellular dysfunction, which suggests the reversible effect of zinc toxicity. 
Each DHA-mediated neuroprotective mechanism presented in this thesis could be 
considered as a potential target for therapeutic intervention against zinc toxicity.  
 
6.5.1 DHA inhibits Zn2+ accumulation and toxicity in neuronal cells 
Chapters 2 and 3 demonstrated the ability of DHA to protect against alteration in 
mitochondrial dysfunction following zinc treatment. Part of this effect could be due 
to neuroprotective function of DHA in regulating [Zn2+]i in the cells, in which DHA 
inhibits excess zinc uptake through decreasing zinc transporter expression levels in 
M17 neuroblastoma cells [45]. Data also showed the ability of DHA to restore zinc-
triggered ROS production, which is mainly due to its free-radical scavenging action as 
supported by in vitro and in vivo studies [345, 346]. In addition to direct attenuation 
of ROS, DHA has been found to restore ATP turnover rate and alteration in proton 
influx and therefore inhibit mitochondrial membrane potential and apoptosis 
(Chapters 2 and 3). Based on these studies, it is important to note that DHA may 
specifically restore zinc-induced mitochondrial alteration, but not directly interact 
with mitochondrial dysfunction following Aβ. Chapter 3 showed that DHA has no 
significant effect on Aβ-mediated ATP turnover, uncoupled respiration, maximal 
respiratory capacity and mitochondrial membrane potential.   
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6.5.2 Anti-apoptotic effect of DHA 
DHA may maintain the integrity of the mitochondrial membrane and prevent the 
release of apoptosis mediators from the mitochondria and therefore block the 
apoptotic caspase cascade. The results showed that DHA treatment in M17 cells 
increases anti-apoptotic Bcl-2 and decreases caspase-3 expression levels (Chapter 5). 
This suggests that following DHA, pro-apoptotic c-jun N-terminal kinase (JNK) may be 
inactivated, followed by “turning off” downstream target c-Jun, which inhibit the 
cleavage of the key effector protease caspase-3, as observed in the study, therefore 
blocking the execution of apoptosis and prevention of nuclear DNA fragmentation, 
the molecular hallmark of apoptosis [347-349]. 
 
DHA may prevent apoptosis, by restoring the reduction of histone protein and mRNA 
levels back to the basal level and abolish the effect of zinc in inhibiting histone 
synthesis and therefore affecting DNA synthesis (Chapter 4). DNA fragmentation 
could also be possibly inhibited by neuroprotective DHA in attenuating ROS 
accumulation due to zinc toxicity. As previously mentioned, the ability of DHA in 
restoring zinc-mediated bioenergetic defects may be the first initiator in inhibiting 
neurotoxicity and cell apoptosis.  
 
The recovery in ATP turnover rate following DHA may also provide the link between 
sufficient energy production and enzyme synthesis required for epigenetic 
regulation. Zinc and DHA have been reported to have opposing effects in epigenetic 
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regulation in M17 cells. Chapter 5 showed that DHA was able to restore epigenetic 
alteration following zinc treatment, which according to current literature has 
downstream effects in inhibiting apoptosis and neurodegenerative conditions. 
Specifically, DHA was shown to decrease HDAC expression and therefore enhance 
histone acetylation [215], which have been reported to be associated with 
neuroprotective gene expression, reduction in intracellular calcium release and 
stabilization of mitochondrial membrane potential [350].  
 
Other studies also suggest the involvement of HDAC inhibitors against several mental 
disorders. Neurodegenerative disease and depression are the pathological conditions 
in which the increase in histone acetylation and reduction in HDACs are the valid 
therapeutic targets [215, 351]. Figure 5.9 showed the neuroprotective affect of DHA 
against epigenetic alteration in M17 neuronal cells and the down stream effects 
leading to cellular survival, based on the current literature. ROS prevention by DHA 
may also contribute to normal epigenetic regulation, as the ROS accumulation has 
been reported to attack DNA and consequently alter base structure leading to 
mutation and cell apoptosis [98, 352]. As a source of cellular energy function, 
increase in ATP production by DHA may also restore the epigenetic pattern by 
inducing effective enzymatic activity, which is required for epigenetic enzyme 
synthesis.  
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Taken together, there are several ways in which zinc toxicity leads to cellular 
dysfunction. However, it seems that there is no way to bypass mitochondria in the 
process of cell apoptosis and neurodegenerative conditions. Mitochondria are pivotal 
for extrinsic and intrinsic apoptotic pathways, which also play a central role in cell 
survival.  DHA has been shown to restore zinc-triggered alteration in mitochondria, 
which may also mediate neuroprotection in other signaling mechanisms, such as 
epigenetic regulation. Finally, this thesis has provided the evidence that zinc 
homeostasis and neuroprotective effect of DHA play an important role in regulation 
of cell survival, which highlights the essential need for further investigation in this 
field.  
 
6.6 CONCLUSION 
The following conclusions can be drawn on the basis of the present findings 
regarding the possible mechanism of zinc toxicity in human neuronal cells and the 
ability of DHA to restore zinc-mediated cellular dysfunction.   
 
1.  Increase in oxidative stress and mitochondrial dysfunction may be the early 
signals of zinc-induced neurotoxicity and apoptosis. This bioenergetic 
impairment caused by zinc leads to the loss of mitochondrial transmembrane 
potential, which may subsequently lead to the formation of membrane 
transition pores and release of caspase activators. DHA is able to restore 
mitochondrial alteration induced by zinc toxicity, which account for the ability 
149 
 
of DHA to stabilize membrane potential, induce anti-oxidant effect to inhibit 
ROS production and preserve overall mitochondrial function.  
 
2.  Mitochondrial dysfunction in response to zinc may also be associated with 
reduction in histone expression levels and therefore affecting DNA integrity in 
neuronal cells. DHA has been shown to be neuroprotective against zinc 
toxicity by increasing histone protein and mRNA expression levels back to 
basal levels, indicating the ability of DHA to abolish the effect of zinc and 
stabilize DNA. Zinc also affects histone PTMs, which is possibly mediated by 
epigenetic enzyme dyshomeostasis and ROS production that subsequently 
alter DNA structure and function. Zinc specifically reduces histone acetylation 
and increases HDACs expression, which therefore inhibit gene transcription, 
whereas DHA restores acetylation dyshomeostasis and therefore increases 
gene regulation. This altered acetylation represents the condition of 
neurodegenerative diseases and apoptosis, mediated by zinc toxicity.  
 
3.  CoQ10 may be more directly protective against Aβ-triggered mitochondrial 
dysfunction than DHA. DHA, due to its direct molecular interaction with zinc, 
may directly protect against zinc-mediated mitochondrial alterations.  
 
4. DHA may offer neuroprotection against zinc-induced toxicity and apoptosis 
that are multifactorial and may act through multiple intracellular signaling 
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mechanisms. Each mechanism presented in this thesis could be considered as 
a potential target for therapeutic intervention of neurodegenerative diseases.  
 
6.8 FUTURE DIRECTION 
The accumulation of endogenous oxygen radicals generated in mitochondria, ATP 
impairment and the consequent oxidative modification of biological molecules have 
been implicated to be responsible for the zinc-induced toxicity. It appears that these 
alterations lead to the formation of mitochondrial permeability transition pores that 
link the neuronal oxidative stress and overall mitochondrial dysfunction leading to 
cellular apoptosis. In this thesis, polyunsaturated fatty acid DHA is suggested to be 
neuroprotective against zinc toxicity in human neuronal cells. However, more 
extensive research is required to investigate the effects of DHA against zinc toxicity in 
relation to mitochondrial function and gene activities as there are still more research 
that needs to be conducted, such as:  
 
1. It would be interesting to look at whether zinc-induced apoptosis is actually 
mediated by the formation of mitochondrial membrane pores, since in our 
current study the zinc-induced mitochondrial membrane pores formation is 
still hypothetical. This could be achieved by perhaps measuring the cytosolic 
release of mitochondrial apoptotic mediator proteins, such as cytochrome c 
or apoptotis inducing factor (AIF), as a result of mitochondrial membrane 
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pores, which are the key events in the mitochondria-dependent apoptotic 
pathway. 
 
2.  Other fatty acids such as the short chain omega-3 and the long chain omega-
6 should be investigated in the future to ensure that the effects observed in 
our studies are indeed DHA-specific. 
 
3.  In vivo studies using an established animal model or primary cultured cells 
would be useful to clinically address the effects of zinc and DHA interaction.  
 
4. To further examine whether DHA could restore zinc-induced mitochondrial 
dysfunction mediated by specific mitochondrial ion channels or proteins that 
contribute to mitochondrial membrane pore regulation, and thus may be 
useful for the therapeutic inhibition of bioenergetic failure and cell death. 
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